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Abstract
Purpose: This study assessed the benefits to the heart and lung of using scanned electron beams
and continuous energy spacing (ΔR90=0.1 cm) for left-side post-mastectomy radiotherapy
(PMRT) patients previously treated with volumetric modulated arc therapy (VMAT). Such
beams offer a sharper distal falloff (R90-10) than do currently available scattered, discrete energy
beams, which increases sparing of healthy organs distal to the target.
Methods: Seven left-side PMRT patients previously treated with VMAT at the Mary Bird
Perkins Cancer Center were planned in this study. The patients were divided into two sets;
Patient Sets 1 (three patients) and 2 (four patients) used one and two fields, respectively, to plan
chest wall irradiation. Four and five intensity modulated bolus electron conformal therapy (IMBECT) plans, respectively, were created per patient using combinations of scattered/scanned and
discrete/continuous energy beam data. For Patient Set 2 the inferior edge of the upper field was
feathered to match the penumbra of the superior edge of the lower field. Dose distributions and
dose volume histograms (DVHs) were used to evaluate plan quality, to calculate physical dose
metrics for the target, heart, and lung, and to calculate the biological metrics, normal tissue
complication probability (NTCP), and secondary cancer complication probability (SCCP) for the
heart and lung.
Results: Scanned and/or continuous energy electron beams showed patient-dependent,
sometimes significant reductions in both physical and biological dose metrics for the heart and
lung. For patient CW1, as compared to scattered, discrete energy beams, scanned, continuous
energy beams reduced V22.5Gy from 10.4% to 2.3%, V30Gy from 3.1% to 0.1%, Dmean from 8.3 Gy
to 4.3 Gy, and NTCP from 0.4% to 0.1% for the heart. The comparison reduced V20Gy from
17.2% to 10.7% and SCCPlin from 14.4% to 8.7% for the lungs. Such reductions tended to

ix

increase as R90 increased. Compared to VMAT, IM-BECT plans with scanned beams on average
reduced V22.5Gy from 9.4% to 3.4%, Dmean from 9.3 Gy to 4.4 Gy, and NTCP from 1.0% to 0.2%
for heart and Dmean from 8.8 Gy to 7.1 Gy, NTCP from 2.8% to 0.2%, and SCCPlin from 15.1%
to 10.2% for lung.
Conclusion: Scanned and/or continuous energy electron beam treatment plans showed reduced
physical and biological dose metrics for heart and lung compared to scattered, discrete energy
beams. These improvements were patient dependent, although patients requiring higher energy
beam(s) tended to show the greatest benefits.
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Chapter 1. Introduction
1.1. Background and Significance
1.1.1. Breast Cancer and Post- Mastectomy Chest Wall Irradiation
In 2019, breast cancer comprised 30% of all new cancer diagnoses in women, the highest
incidence rate of all cancers in women.1 While the overall cancer incidence rate for women has
stayed relatively constant over the past few decades, breast cancer incidence rates have been on
the rise. From 2006 to 2015 in the United States, breast cancer incidence increased by 0.3%-0.4%
per year in non-Hispanic white and Hispanic women, by 0.7%-0.8% per year in black and
American Indian/ Alaska Native women, and by 1.8% per year in Asian/ Pacific Islander women.2
Contributing factors may be the obesity epidemic and declining parity.3, 4
15% of all deaths due to cancer, corresponding to 41,760 total patients, were attributed to
breast cancer in the United States, which has the second highest mortality rate of all cancers in
women. However, the 5-year survival rate for all stages of breast cancer is 90%, which is the third
highest of all cancers.1 This suggests that the high mortality rate is primarily due to its high
incidence rate.
Surgery, radiation, or a combination of the two are common treatment options for breast
cancer. A mastectomy, complete removal of the breast tissue, is often combined with radiotherapy
to eradicate microscopic disease in the remaining chest wall, referred to as post-mastectomy
radiotherapy (PMRT).
When planning post-mastectomy radiation treatments, the chest wall is defined by the
following anatomical boundaries based on consensus definitions from RTOG breast cancer Atlas:
to the caudal border of the clavicle head on the cranial side, to the skin on the anterior side, to the
rib-pleural interface (including the pectoralis muscles, chest wall muscles, and ribs) on the
posterior side, to the mid axillary line (excluding latissimus dorsi) on the lateral side, to the sternal1

rib junction on the medial side, to the clinical reference on the caudal side.5 The supraclavicular
region, which is treated with photon radiotherapy, has the following anatomical boundaries based
on the RTOG breast cancer Atlas: the upper border is below the level of the cricoid, the medial
border is at the vertebral pedicles and lateral border consists of the portion of the axilla that
remained undissected, and the inferior border extends to the caudal aspect of the clavicular head.5
See Figure 1.1 for outlines of the regions and heart.

Figure 1.1. RTOG breast cancer atlas image of chest wall: sagittal (upper left), coronal (upper
right), and transverse (lower right) planes. Shown are the chest wall, heart, and internal mammary
glands.6
The standard radiation dose for post-mastectomy radiotherapy is 50 Gy to the target,
delivered as 2 Gy daily fractions over 5 weeks. Monitor units are calculated to give the prescribed
2

dose to 95% of the target volume.7, 8 Due to the high survival rate, the long-term side effects of
post-mastectomy radiotherapy must be examined. For any post-mastectomy radiotherapy
treatment, the lung is a primary organ at risk. In addition, for cases involving left-side postmastectomy chest wall irradiation, the heart is also of concern, as the heart is distal to the left side
of the chest wall. Cardiac late effects such as pericarditis, ischemic heart disease, congestive heart
failure, and coronary atherosclerosis can occur if the dose delivered to the heart is too high.9
However, if the heart receives under 30 Gy of dose, there is not an increased risk of cardiac
mortality.10 Thus, the present study evaluates the risk of developing radiotherapy side effects to
the heart with V30 Gy, the volume of the heart receiving at least 30 Gy of dose compared to the total
heart volume. Radiation pneumonitis, or acute inflammation of the lung, and pulmonary fibrosis,
or scarring and stiffening of scar tissue, can both occur if too large a volume of the lung is
irradiated.11 Thus, the present study evaluates the risk of developing radiotherapy side effects to
the lung with V20 Gy, the volume of the lungs receiving at least 20 Gy of dose compared to the total
lung volume.12, 13
Because of the improvement in overall survivorship for invasive breast cancer patients
when using PMRT, many different advanced radiotherapy techniques have been developed. These
techniques include fixed-beam intensity-modulated radiotherapy,14 non-coplanar volumetric
modulated arc therapy (VMAT),15 multiple arc VMAT,16 mixed beam therapy (photons and
electrons),17 electron arc therapy,18 and helical tomotherapy19. A previous study conducted by Xie
et al.20 evaluated many of these different treatment modalities for treating PMRT patients by the
following metrics: planning target volume (PTV) coverage, dose homogeneity index (DHI),
conformity index (CI), dose to organs at risk (OARs), normal tissue complication probability
(NTCP) of pneumonitis, lifetime attributable risk (LAR) of second cancers, and risk of coronary
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events (RCE). They found that fixed-beam IMRT delivered the lowest mean dose to contralateral
breast and exhibited lowest LAR of secondary contralateral breast cancer; non-coplanar-VMAT
delivered the lowest mean dose to lungs, exhibited lowest LAR of secondary lung cancer and
lowest NTCP of pneumonitis; mixed beam therapy delivered the lowest mean dose to heart and
exhibited lowest RCE for the heart; and tomotherapy plans provided the most optimal target
coverage while delivering higher dose to OARs than other techniques.
Opp et al.21 performed a similar study to compare the following PMRT techniques:
opposed tangents with wedges, opposed tangents with field in field modulation, 8-field IMRT, and
bolus electron conformal therapy (BECT). They compared the dose homogeneity and normal
tissue dose parameters for these four sets of plans while maintaining a constant PTV coverage.
They found that IMRT and BECT provided the lowest V25 Gy doses for the heart, while field in
field had the lowest average lung dose. In addition, IMRT provided the lowest V20 Gy doses for the
lung and BECT provided the lowest mean heart dose. This study, along with Xie et al.’s study
shows that using electron radiotherapy for PMRT has OAR sparing benefits while maintaining
adequate PTV coverage.
1.1.2. Electron Beam Radiation Therapy
Therapeutic electron beams are characterized by a unique depth dose profile and finite
range that can be useful for irradiating planning target volumes (PTVs) within 6 cm of the patient
skin surface while sparing distal organs and tissues. Superficial cancers and shallow tumor sites,
such as skin, spinal cord, head and neck, and chest wall are effectively treated with electron
beams.22–24 This includes PMRT, for which there are many electron beam techniques, such as
abutted beams of different energies,19 electron arc therapy,18 and BECT.21, 25, 26
Clinically available electron beams typically have energies ranging from approximately 7
MeV to 20 MeV, which have therapeutic ranges (R90) of approximately 2.0 cm to 6.0 cm,
4

respectively. Such electron beams deliver a fairly uniform dose from the surface to R90, with a
sharp distal falloff (R90-10), which spares underlying healthy tissue and critical organs. This rapid
dose falloff beyond the target volume depth decreases the normal tissue complication probability
while preserving high tumor control. This is the primary advantage of electron beam therapy over
conventional photon therapy. Figure 1.2 characterizes the depth dose profile of an electron beam.

Figure 1.2. Characteristic depth dose curve of a megavoltage electron beam. The dose is
normalized at R100, the depth of maximum dose. The maximum dose, Dm or 100%, does not occur
at the surface, but deeper in the volume, due to multiple Coulomb scattering. Typically the dose
ranges from the lesser of Ds or 90% to 100% in the planning target volume (PTV). 27, 28
Typically, electron beams are delivered in such a way that as much of the PTV is contained
in the plateau (surface to R90 depth) with dose ranging from 100% to 90% (or Ds, if lower) without
overdosing distal healthy tissue. In three dimensions, distal PTV depth varies with off-axis
position, and ideally, the lowest energy that can contain the PTV within the 90% isosurface should
be used. Often a higher than required energy is used in conjunction with a tissue-equivalent bolus
to treat the PTV, due to the discretely spaced energies of clinically available electron beams, as
illustrated in Figure 1.3 for the Elekta radiotherapy accelerator. In such a case, a tissue-equivalent
bolus usually is placed superficial to the target, shifting the dose distribution towards the surface
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and R90 toward the distal PTV surface. Note in Figure 1.3 that higher energy electron beams have
a more gradual falloff (increased R90-10), delivering more dose to healthy tissues distal to the PTV.
This effect is amplified in lung, compared to unit density tissue, due to its lower density
(approximately 0.25-0.33 times that of unit density tissue).

Figure 1.3 Percent depth dose curves for clinically available Elekta energies at Mary Bird Perkins
Cancer Center (MBPCC). Note that higher energy beams that are more penetrative have a greater
dose falloff region (R90-10).
1.1.3. Scanned Electron Beams
Historically, two methods have been used for broadening and flattening therapeutic electron
beams: dual scattering foil and scanned beams. Dual scattered electron beams use a thin high-Z
metal foil (placed 90-100 cm upstream of isocenter) to broaden the beam and a Gaussian-shaped
metal foil, typically aluminum (placed 5-20 cm downstream of primary foil) to flatten the resulting
forward peaked beam.29, 30 Scanned electron beams use two scanning dipole magnets to scan the
electron beam in orthogonal directions to spread and flatten the beam. The scanning patterns can
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be row by row, spiraled, or quasi random.31 Because scanned beams do not have the thick primary
scattering foil, there is less bremsstrahlung production and energy straggling in the treatment head,
reducing R90-10.
Hence, scanned beams can offer superior dose distributions compared to scattered beams,
which can have clinical advantages. This is illustrated in Figure 1.4, which compares a scattered
and a scanned beam, each having an R90 of 5.0 cm. Note the difference in the dose falloff region:
the scanned beam having a lower R90-10, reduced Rp (corresponding reduced beam energy, Ep,0),
and reduced D.

Figure 1.4. Percent depth dose curve for both a scanned (Therac 20) and scattered (Elekta) electron
beam with R90 of 5.0 cm. The R90-10 of the scanned beam is 2.42 cm, versus 3.01 cm for the
scattered beam, which corresponds to 0.59 cm of additional normal tissue sparing.
These effects are illustrated in Figure 1.5, which compares plots of R90 vs Ep,0 and R90-10 vs
Ep,0 for scattered and scanned beams. The increased benefit of scanned beams can be better
7

appreciated by combining the data of Figure 1.5 into a plot of R90-10 versus R90 for scattered and
scanned beams, shown in Figure 1.6. For example, an R90 of 5.0 cm requires a 16.2 MeV scattered
beam versus a 15.05 MeV scanned beam (demarcated in Figure 1.5), which results in a decreased
R90-10 (3.0 cm versus 2.4 cm), decreased Rp (7.9 cm vs 7.4 cm), and decreased D. Thus, a lower
energy scanned beam can be used to treat the same target as a scattered beam, while providing
additional healthy tissue sparing. Unfortunately, due to specific cases of overdose due to scanning
failures, scanning beam electron therapy machines were phased out in the 1990s, and currently
scattered electron beams are almost exclusively used clinically.32

Figure 1.5. R90 and R90-10 as a function of energy for both scanned and scattered beams in water.
The scanned electron beam has a greater R90 for each energy compared to the scattered beam and
has a lower R90-10 for each energy compared to the scattered beam. Points demarcate discrete
energies on selected Therac 20 and Elekta machines, and solid lines are guides for the eye. The
dashed lines indicate Ep,0 of beams having R90 of 5.0 cm.
1.1.4. Continuous Beam Energy
Another impact on the distal dose falloff is the spacing between discrete electron beam
energies for both scattered and scanned electron beam radiotherapy machines. This is illustrated
in Figure 1.6, where electron beam energies are indicated by the points, showing that energies are
spaced at approximately 0.5 to 1.0 cm R90 intervals in water, which corresponds to approximately

8

1.5 to 4.0 MeV intervals in Ep,0. The impact of this is illustrated in Figure 1.7, which compares
scattered beam %DD curves of a beam with an R90 of 5.2 cm with one having an R90 value of 5.9
cm with 0.7 cm of bolus. In such a case, the R90-10 is 3.4 cm vs. 4.3 cm, illustrating the downside
of having to use a higher energy with bolus when continuous energies are not available.

Figure 1.6. R90-10 as a function of R90 for both scanned and scattered beams in water. The scanned
beam has a lower R90-10 for each R90 than the scattered beam, so that there is less dose falloff for
treating the same depth. Points demarcate discrete energies on selected Therac 20 and Elekta
machines. Solid lines are guides for the eye, and the dashed lines indicate scattered beams with
R90=5.9 cm + 0.7 cm bolus and R90=5.2 cm and a scanned beam with R90=5.2 cm.
In addition to continuous energy beams, if scanned beams were available, R90-10 would be
further reduced to 2.5 cm. Hence, compared to the scattered, discrete energy beam, the scanned
continuous energy beam reduces R90-10 by almost 2 cm (from 4.3 to 2.5 cm). This advantage is
further illustrated by comparing the corresponding depth dose curves in Figure 1.7, which first
simulates the water-equivalent heart lying 0.5 cm distal to the 5.2 cm deep PTV, and second it
simulates the 0.25 density lung lying 1.0 cm distal to the 5.2 cm deep PTV.
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Figure 1.7. Comparison of percent depth doses curves for continuous versus discrete spacing for
two scattered Elekta beams and for scanned, continuous energy Therac beam. Percent depth dose
curves for the scattered electron beams have an Ep,0=17 MeV and Ep,0=20.5 MeV+0.7 cm bolus
(both corresponding to R90=5.2 cm). Percent depth dose curves for the scanned beam have an
Ep,0=15.6 MeV (corresponding to R90=5.2 cm). Shown for heart lying distal to the PTV (top) and
lung lying distal to PTV (bottom). The red dashed lines indicate the starting depth for which the
DVHs in Figure 1.8 are generated.
These effects of using scanned, continuous energy beams over scattered, continuous energy beams
over currently available scattered, discrete energy beams are demonstrated in DVHs for a
simulated patient geometry, as shown in Figure 1.8. These DVHs are generated from the percent
depth dose curves shown in Figure 1.7.
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Figure 1.8. Simulated DVHs for a generic patient, shown for the heart (left) and lung (right). All
three beams shown are used to treat a target that is 5.2 cm thick. Using percent depth dose curves
in Figure 1.7, the heart V30Gy is reduced from 28% to 18% to 12%, and the lung V20Gy is reduced
from 24% to 14% to 8%, when using scattered, discrete energy beams (green line)scanned,
continuous energy beams (blue line) versus scanned, continuous energy beams (blue line),
respectively.
While these discretely spaced electron energies can effectively treat patients, they can
introduce greater dose to normal tissue than an ideal treatment. The ability to select the optimal
beam energy from a set of continuously variable electron energies and/or use scanned beams versus
scattered beams could provide the ability to improve patient treatments by delivering less dose to
normal tissues than using currently available electron beams. To further investigate this concept,
we believe it appropriate to utilize the most technically advanced method for electron planning
and delivery currently available, intensity modulated bolus electron conformal therapy (IMBECT).33, 34
1.1.5. Intensity Modulated-Bolus Electron Conformal Therapy (IM-BECT)
Electron conformal therapy (ECT) is the use of one or more electron beams to contain the
PTV to the 90% dose surface, achieve as homogenous dose distribution as possible or a prescribed
heterogeneous dose distribution to the PTV, and deliver minimal dose to underlying critical
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structures and normal tissues.35 Bolus ECT (BECT) has been shown clinically useful for posterior
chest wall,25, 36 PMRT,21, 25, 26 head and neck,33, 37 and extremities.36 Currently, BECT planning
and delivery technology is commercially available from .decimal LLC (Sanford, FL) and from
Adaptiiv (Halifax, NS, Canada), which are based on the original work of Low et al.38 and a later,
similar work by Su et al,36 respectively. These technologies use a bolus (tissue equivalent range
compensator) that shapes the distal side of the dose distribution (e.g. 90% dose surface) to the
PTV. The bolus can be milled machinable wax39 or 3D printed polyethylene terephthalate glycolmodified (PETG) or polylactic acid (PLA).36, 40 The bolus is patient-specific, and its distal surface
conforms to the patient surface. However, bolus electron conformal therapy (BECT) can produce
increased dose heterogeneity in the PTV due to the irregular proximal surface of the bolus creating
lateral side scatter disequilibrium.
Kudchadker et al. showed that intensity modulation used in conjunction with BECT can
significantly improve dose homogeneity in the PTV.33 In this case, the bolus provides a high level
of dose conformation to the PTV, and the intensity modulation improves dose homogeneity,
reducing hot and cold spots.
Recently, a new technology for passive electron intensity modulation has been developed
and studied.34, 41–43 For intensities 50% or greater of the incident beam, modulation is achieved
using tungsten island blocks of varying diameters placed on a hexagonal grid and embedded in
low density, machinable foam within the patient collimating aperture. The block diameters are
selected to modulate electron fluence, analogous to metal compensators used in intensity
modulated x-ray therapy.34 Intensity modulation is useful for delivering a highly conformal and
homogenous (or prescribed heterogeneous) dose distribution.
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A later study by Kudchadker et al. showed the improvement in dose distribution as well as
the reduction of hot and cold spots when using IM-BECT over BECT for the post-mastectomy
chest wall.33 These results are shown in Figure 1.9.
1.2. Motivation for Research
Opp et al. compared bolus electron conformal therapy with conventional techniques for the
treatment of left-side chest-wall post-mastectomy patients.21 That study completed treatment plans
for twenty-five patients comparing opposed tangents with wedges, opposed tangents with field-infield modulation, 8-field IMRT, and BECT. Results showed that IMRT and BECT provided the
lowest heart V25 Gy doses, and BECT had the lowest mean heart dose. Field-in-field provided the
lowest mean total lung dose and IMRT provided the lowest total lung V20 Gy. In some cases, BECT
could not provide adequate coverage, and IMRT showed better dose homogeneity. When using
IMRT, the contralateral breast and lung receive slightly higher doses compared to other techniques.
Patient anatomy determines whether BECT is suitable, and patients with a maximal target depth
of <5.7 cm could be treated with BECT. If the maximal depth of the target is >5.7 cm, IMRT
provides better dose homogeneity and normal tissue sparing.21
Previous work has shown that using IM-BECT over the heart and opposed IMXT elsewhere
for PMRT has statistically significant advantages over using conventional techniques such as
VMAT in some patients.43 Delivering IM-BECT treatments to the chest wall with scanned beams
and continuously spaced energies should further reduce the dose to the heart and lung in PMRT.
In the present study, only the chest wall portion of the PTV treated in PMRT, which can be
treated with IM-BECT, will be studied, i.e. the supraclavicular PTV, normally requiring x-ray
radiotherapy will be ignored. The chest wall treatment will be planned using one field, or if needed,
two abutted fields, the lower “heart field” and upper “lung field.” The heart field will be treated
with a lower energy, and the lung field will be treated with a higher energy. The objective of this
13

study is to verify and quantify the benefits of using scanned electron beams and/or continuously
spaced electron beam energies for chest wall PMRT.

Figure 1.9. Dose distributions comparing BECT and IM-BECT for post-mastectomy chest wall.33
The PTV is marked with the dashed line in the transverse plane shown. (a) BECT resulting in a
hot spot of 109.3% and (b) IM-BECT resulting in a reduced hot spot of 106.7%.
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1.3. Hypothesis and Specific Aims
1.3.1. Hypothesis
For seven post-mastectomy radiotherapy left-side chest wall patients previously treated
with volumetric modulated arc therapy (VMAT), treatment plans using intensity modulated bolus
electron conformal therapy (IM-BECT) with a scanned electron beam and/or the capability of
continuous energy spacing can be superior (increased sparing of heart and lung and reduced chance
of secondary cancer) to plans made using IM-BECT with a passively scattered electron beam and
discrete Elekta energy spacing.
1.3.2. Specific Aims
Aim 1, Generate Treatment Plans Assuming Different Electron Beam Technology: Generate IMBECT treatment plans for seven post-mastectomy radiotherapy (PMRT), left-side chest wall
patients previously treated with volumetric modulated arc therapy (VMAT) using a range of
applicable energies from 13 to 20 MeV. Treatment plans will be generated for combinations of
scanned or passively scattered electron beams and discrete or continuous electron energy beams.
Plans will be developed for the entire chest wall PTV, which had been contoured in accordance
with RTOG breast cancer atlas guidelines while maintaining healthy tissue dose limits. Compute
3D dose distributions and DVHs for each plan.
Aim 2, Physical and Biological Dose Metrics for Plans: Compute physical dose metrics and
resulting biological metrics for each of the plans for each of the seven patients. Physical dose
metrics include (1) PTV: Dmax(maximum dose), Dmean (mean dose), D97% (Dose given to 97% of
PTV volume) and V47.5 Gy (relative volume of PTV receiving 47.5 Gy, or 95% of the prescribed
dose of 50 Gy), (2) Heart: Dmin, Dmax, Dmean, V22.5 Gy (relative volume of heart receiving 22.5 Gy),
and V30 Gy (relative volume of heart receiving 30 Gy), and (3) Lung: Dmin, Dmax, Dmean, and V20 Gy
(relative volume of lung receiving 20 Gy). Biological dose metrics include (1) Heart: NTCP
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(normal tissue complication probability) and (2) Lung: NTCP, SCCPlin (secondary cancer
complication probability, linear model), and SCCPlin-exp (secondary cancer complication
probability, linear-exponential model).
Aim 3, Analyze and Compare Plans using Metrics: Analyze the seven different sets of patient
plans and determine the patient indications for using continuously spaced electron energies and
scanned electron beams. Determine the differences in patient geometry and beam conditions that
affect the utility of scanned versus scattered beams and continuous versus discrete energy
spacing (Comparisons made in this aim are presented in the discussion section).
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Chapter 2. Methods and Materials
2.1. Aim 1—Generating Treatment Plans Assuming Different Electron Beam Technology
The goal of Aim 1 is to develop IM-BECT plans for seven post-mastectomy radiotherapy
left-side chest wall patients previously treated with volumetric modulated arc therapy (VMAT).17
For each plan, this involves the following steps:
1. Create initial electron plan.
a. Beam Angle Selection
b. PTV Segmentation
c. Field Construction
d. Energy Selection
2. Improve beam penumbra matching using edge feathering.
3. Design electron bolus for each field.
4. Compute dose distributions for each field.
5. Sum for the composite chest wall dose distribution.
Steps 1 and 2 were completed using Pinnacle v9.10 (Philips Radiation Oncology Systems,
Fitchburg, WI) treatment planning system and MATLAB code developed for this project. Steps 3
and 4 were completed using a research version of p.d (.decimal LLC, Samford, FL). MIM (MIM
Software Inc., Cleveland, OH) was used to assist in transferring files between platforms,
completing step 5, and evaluating plan quality.
For all plans, the prescription was 50 Gy to the 90% isodose line (100%, or 55.6 Gy, is the
given dose for each field) in 25 fractions. However, to compare plans for the same patient, dose
distributions were rescaled, so all plans delivered an identical dose to 50% of the PTV, based on
the dose given to 50% of the PTV for Plan 1, defined later.
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2.1.1. Patient Selection
Seven left-side post-mastectomy chest wall patients were selected, each of whom fulfilled
the following criteria:
1. Received prior treatment with VMAT at the Mary Bird Perkins Cancer Center
2. Part of a HIPAA compiled data set
3. Subjects of previous retrospective treatment planning study by Heins8 (2016) and
Doiron41 (2018).
Each anonymized patient data set included previously defined contours (PTVs, normal
structures, and skin surface) and CT images acquired on a 120 kVp large bore GE Lightspeed 16
CT scanner (General Electric Medical Systems). Transverse CT planes were acquired every 0.25
cm. The chest wall PTV and organs at risk, i.e. lung and heart, were previously contoured by the
treating radiation oncologist. The patients and their corresponding data sets are referred to as CW1
through CW9 (CW5 and CW9 were not included in this study due to software issues in our research
version of p.d), matching the designations in Heins and Doiron.8, 41
For planning purposes, the patient data was divided into two subsets, Patient Set 1 (CW1,
CW3, CW6) and Patient Set 2 (CW2, CW4, CW7, CW8). Patient Set 1 was planned using a single
field (single energy); Patient Set 2 was planned using two abutting fields (having different beam
energies).
2.1.2. Field Specifications for Patient Set 1
For three patients (CW1, CW3, and CW6), further referred to as Patient Set 1, one electron
field (energy) was sufficient to cover the entire PTV. In these cases, the deepest part of the PTV
superficial to the heart is as deep or deeper than the portion of the PTV superior to the heart. Hence,
only one PTV and one beam energy were necessary. The superior and inferior margins were set as
2 cm, and the two lateral margins are set as 1.5 cm. Only four plans, Plan 1, Plan 3, Plan 4, and
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Plan 5, were created for these patients (CW1, CW3, and CW6), corresponding to the plan
designations described for Patient Set 2. A schematic of the fields and PTVs for each plan is shown
in Figure 2.1.

Figure 2.1. Schematic of PTVs and fields for Patient Set 1. For these patients, the superior border
of the CW PTV (PTV Evaluate) is at the inferior border of the supraclavicular PTV (SC PTV).
2.1.3. Field Specifications for Patient Set 2
For four of the seven patients (CW2, CW4, CW7, and CW8), further referred to as Patient
Set 2, the chest wall PTV was divided into two separate PTVs: the inferior (lower) PTV which is
anterior to the heart and the inferior portion of the left lung, and the superior (upper) PTV which
is anterior to lung, extending from the superior border of the inferior field to just inferior to the
PTV for the supraclavicular nodes. The supraclavicular nodes were assumed to have been planned
with x-rays which contribute insignificant dose to lung, hence not included in this study. The
superior border of the PTV was located at the caudal aspect of the clavicular head. The lower PTV
was shallower and treated with a lower energy electron beam, while the upper PTV was deeper
and treated with a higher energy electron beam. This allowed dose to the heart to be minimized.
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For these patients, the planned treatment used two abutted fields, each having different
energies and irradiating separately the previously defined PTVs. Five plans were created for each
patient; Plans 1,2, and 4 had the same PTVs (fields), illustrated in Figure 2.2, while Plans 3 and 5
had the same PTVs (fields), illustrated in Figure 2.3.
For Plans 1, 2, and 4 (Figure 2.2) the lower PTV extended from the inferior extent of the
PTV to the farthest extent superior to the heart that could be treated using the lowest energy from
the set of available discrete energies sufficient to treat the PTV anterior to the heart. For planning
purposes, a 2 cm junction PTV was placed between the lower and upper PTVs. The upper PTV
extended from the superior extent of the junction PTV to the supraclavicular PTV, which has an
inferior border at the caudal aspect of the clavicular head. The lower PTV, junction PTV, and
upper PTV together comprised the chest wall PTV used to evaluate plan quality, also referred to
as the PTV Evaluate. The lower PTV was treated with the lower field, which had a 1.5 cm lateral
expansion, a 2.0 cm inferior expansion, and a 1 cm superior expansion of the lower PTV. The
upper PTV was treated with the upper field, which had a 1.5 cm lateral expansion, a 1 cm inferior
expansion, and a 2.0 cm superior expansion of the upper PTV.
For Plans 3 and 5 (Figure 2.3), the lower PTV extended from the inferior extent of the PTV
to the superior extent of the heart. The selected energy is the lowest from a set of available
continuous energies sufficient to treat the PTV superficial to the heart. For planning purposes, a 2
cm junction was placed between the lower and upper PTVs. The upper PTV extended from the
superior extent of the junction PTV (PTV Evaluate) to the supraclavicular region, which has an
inferior border at the caudal aspect of the clavicular head. The lower PTV, junction, and upper
PTV together comprised the PTV used to evaluate plan quality, also referred to as the Chest Wall
PTV. The lower PTV was treated with the lower field, which had a 1.5 cm lateral expansion, a 2.0
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cm inferior expansion, and a 1 cm superior expansion of the lower PTV. The upper PTV was
treated with the upper field, which had a 1.5 cm lateral expansion, a 1 cm inferior expansion, and
a 2.0 cm superior expansion of the upper PTV.

Figure 2.2. Schematic of the PTVs and fields for Plans 1,2, and 4 for each patient. For these plans
the superior border of the lower PTV is at the farthest superior extent that can be covered with the
lower energy beam. The chest wall PTV (PTV Evaluate) is comprised of the upper PTV (orange
region outlined by dashed lines), the lower PTV (green region outlined by dashed lines), and the
intervening junction PTV (outlined by dashed lines). Lower field is light green region outlined by
solid black line; upper field is light orange region outlined by solid black line.
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Figure 2.3. Schematic of PTVs and fields for Plans 3 and 5 for each patient in Patient Set 2. For
these plans the superior border of the lower PTV is at the superior edge of the heart. Assuming
availability of beams with continuous energy, Plans 3 and 5 beams are flattened using dual
scattering foils and scanned beams, respectively. The chest wall PTV (PTV Evaluate) is comprised
of the upper PTV (orange region outlined by dashed lines), the lower PTV (green region outlined
by dashed lines), and the intervening junction PTV (outlined by dashed lines). Lower field is light
green region outlined by solid black line; upper field is light orange region outlined by solid black
line.
2.1.4. Electron beam arrangements for Patient Set 1
For Patient Set 1 an SSD of 105 cm was used, and the gantry angle was selected so the
beam central axis was approximately perpendicular to the distal PTV surface, typical of BECT
plans, which resulted in a left, anterior, oblique field. The beam parameters (i.e. gantry angles,
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SSD, and field shape) were determined in Pinnacle3 and exported to p.d for use during bolus
design.
2.1.5. Electron beam arrangements for Patient Set 2
For Patient Set 2, each plan consisted of three beams, one lower energy beam that covered
the lower field, and two higher energy beams covered the upper field. The two upper fields were
identical except for their lower edges, which were feathered so that their composite penumbra
closely matched that of the lower field, maximizing dose homogeneity in the abutment region. All
three beams shared a common isocenter and a common virtual source, i.e. common beam central
axis. Each beam had a source-to-surface distance (SSD) of 105 cm along the common central axis,
typically used to prevent collisions between the electron applicator and electron bolus. As was the
case for Patient Set 1, the gantry angle was selected so that the beam central axis was
approximately perpendicular to the distal PTV surface, typical of BECT treatment plans. The beam
parameters (i.e. gantry angles, SSD, and field shape) were determined in Pinnacle3 and exported
to p.d for use during bolus design.
2.1.5.1.

Upper field edge feathering for dose homogeneity at abutment of high and low energy
fields

Perfect penumbra matching between the upper and lower fields was impossible due to the
different beam energies, as well as patient surface irregularities. To mitigate hot and cold spots,
edge feathering of the upper (higher) energy beams was used. Figure 2.4 illustrates the need for
edge feathering by using CW2 fields in water as an example, and Figure 2.5 illustrates how edge
feathering was implemented in this study to improve dose homogeneity in the abutting region.
Two identical copies of the upper field were created, then the inferior borders of the fields were
shifted +/- Δ, where Δ depended on six factors: beam energy, PTV depth (z), and distance between
the collimator and bolus surface (L0) for the lower and upper fields. These factors are illustrated
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in Figure 2.6. The parameters used to determine Δ for patient plans in Patient Set 2 are shown in
Table 2.1.
The optimal edge feathering parameter, Δ, was determined by matching the penumbra of
the lower and upper fields. This was done by minimizing the square of the residuals between the
relative intensity functions for the lower field, 𝑓(𝑥), and for the upper field, (𝑔+Δ (𝑥) +
𝑔−Δ (𝑥))/2, where 𝑓 and 𝑔 were found by following:
𝑤0
−𝑥
2

1

𝑓(𝑥) = 2 [erf (

1

√2𝜎𝑥

) + erf (
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−𝑥
2
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+𝑥
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√2𝜎𝑥

)] .

Here, x is the distance from the center of the upper field to the edge of the abutting edge. 𝑤0 and
𝜎𝑥 are patient dependent, depending on the energy and geometry of each of the abutted fields,
illustrated in Figure 2.6. The latter is given by
𝜎𝑥2 = (𝑧 + 𝐿0 )2 𝜎𝜃2𝑥 + 𝑎2 (𝑧)
𝑧 is the distance from the bolus surface to a depth equal to half the chest wall PTV thickness below
the skin surface at the abutment location, 𝐿0 is the distance from the bottom edge of the electron
cutout/applicator to the bolus surface, and 𝑎2 (𝑧) is the RMS spread of the lateral distribution of
electron beams incident on the bolus at depth (z) equal to the distance from the bolus surface to
half the chest wall PTV thickness in the patient. 𝑎2 (𝑧) was determined using the formalism of
Werner et al.44 The optimization of Δ was determined using the L2 norm in a MATLAB program
developed for this study.
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(
a)

(
b)

Figure 2.4. Off-axis dose distributions for two abutting fields are shown for CW2. (a) Without
feathering, there is a +/- 11% dose heterogeneity. (b) When feathering the lower border of the
upper field, the dose heterogeneity has been reduced to +/- 4%. See Table 2.1 for values of six
parameters.
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Figure 2.5. Beam’s eye view illustrating feathering lower edge of the upper field (±Δ) abutted to
lower field.

Figure 2.6. Side view illustrating six parameters that affect Δ when determining feathering of upper
field penumbra to match that of lower field.
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Table 2.1. Parameters used to calculate Δ for Patient Set 2. All values are shown for Plan 1, which
has discrete energy spacing and uses scattered electron beams.
Lower Lower Lower
Upper Upper Upper
Lower
Upper
Δ
Patient Energy
R90
L0
Energy
R90
L0
z (cm)
z (cm) (cm)
(MeV)
(cm)
(cm)
(MeV)
(cm)
(cm)
CW2

13.0

4.0

6.9

3.6

16.2

5.0

5.9

4.6

0.7

CW4

16.2

5.0

8.0

4.0

21.3

6.0

7.0

5.0

0.8

CW7

16.2

5.0

6.1

4.5

21.3

6.0

5.1

5.5

0.7

CW8

13.0

4.0

7.6

3.2

16.2

5.0

6.6

4.2

0.6

2.1.6. Energy Selection for Different Plans
Table 2.2 lists R90 and R90-10 values for the energies available on the Elekta Infinity
(scattered beams), and Table 2.3 shows the R90 and R90-10 values for R90 values corresponding to
the Elekta Infinity for the Therac 20 (scanned beam). These discrete energies were used to create
and evaluate treatment plans with discrete energy spacing.
For each patient, either four plans (Pans 1,2,4,5) were created (Patient Set 1) or five plans
(Plans1-5) were created (Patient Set 2). Described as follows, the different plans investigated the
effects of scattered versus scanned beams as well as the effects of continuous energy spacing.
Table 2.2. Available electron energies on the Elekta Infinity at MBPCC, as well as corresponding
R90 and R90-10 values in water. In the case where the depth of the target falls between two R90
values, the higher energy must be used. Continuously spaced electron energies will prevent
unnecessary additional dose to distal normal tissue.
Nominal Energy (MeV)
Ep,0 (MeV)
R90 (cm)
R90-10 (cm)
7

7.0

2.0

1.4

9

8.4

2.5

1.7

10

9.9

3.0

1.9

11

11.4

3.5

2.1

13

13.0

4.0

2.4

16

16.2

5.0

3.0

20

21.3

6.0

4.4
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Table 2.3. Beam parameters of Therac 20 for R90 values corresponding to the same R90 values as
available electron energies on the Elekta Infinity. Also shown are the corresponding Ep,0 and R9010 values. In the case where the depth of the target falls between two R90 values, the higher energy
must be used. Continuously spaced electron energies will prevent unnecessary additional dose to
distal normal tissue.
Nominal Energy (MeV)
Ep,0 (MeV)
R90 (cm)
R90-10 (cm)
7

6.5

2.0

1.1

9

8.9

2.5

1.4

10

9.4

3.0

1.5

11

10.8

3.5

1.8

12

12.1

4.0

2.0

15

15.1

5.0

2.4

18

18.3

6.0

3.0

Plan 1, Scattered, Discrete Energy Beams:
For Plan 1, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The
minimum commercially available energy (from Table 2.2), whose 90% dose surface (R90) could
sufficiently cover the entire PTV, was selected.
For Plan 1, Patient Set 2, the PTVs and fields were planned as shown in Figure 2.2. The
minimum commercially available Elekta scattered beam energy (see Table 2.2) for each beam,
whose 90% dose surface (R90) could sufficiently cover the lower or upper PTVs, was selected.
Plan 2, Scattered, Discrete and Continuous Energy Beams:
For Patient Set 1 no Plan 2 was created, as there was no upper field. For Plan 2, Patient Set
2, the PTVs and fields were created as shown in Figure 2.2. The lower field was planned using the
same field as in Plan 1. Different from Plan 1, the upper field was planned with the minimum
energy, assuming continuous energy beams, whose 90% dose surface (R90) could sufficiently
cover the upper PTV, assuming availability of continuous energy spacing. Both fields were treated
with scattered electron beams.
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Plan 3, Scattered, Continuous Energy Beams:
For Plan 3, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The PTV
was planned using a single beam with the minimum energy whose 90% dose surface (R90) could
sufficiently cover the upper PTV, assuming availability of continuous energy spacing for scattered
Elekta beams.
For Plan 3, Patient Set 2, the PTVs and fields were created as shown in Figure 2.3. The
lower field was planned using the minimum energy whose 90% dose surface (R90) could
sufficiently cover the lower PTV, assuming availability of continuous energy spacing for scattered
Elekta beams. The upper field was treated with the lowest energy, whose 90% dose surface (R90)
could sufficiently cover the upper PTV, assuming availability of continuous energy spacing for
scattered Elekta beams.
Plan 4, Scanned, Discrete Energy Beams:
For Plan 4, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The PTV
was planned using a single beam by selecting the minimum discrete beam energy, whose 90%
dose surface (R90) could sufficiently cover the entire PTV. The single scanned beam energy was
selected from Therac 20 scanned electron beams energies, assumed to have the same discrete R90
values as commercially available Elekta beams (from Table 2.3).
For Plan 4, Patient Set 2, the PTVs and fields were created as shown in Figure 2.2.
Assuming Therac 20 scanned electron beams energies, having the same discrete R90 values as
commercially available Elekta beams (from Table 2.2), a plan was developed the same as done
using scattered beams in Plan 1. That is, the minimum energy beams whose 90% dose surface
(R90) could sufficiently cover the lower and upper PTVs, were selected.
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Plan 5, Scanned, Continuous Energy Beams:
For Plan 5, Patient Set 1, the PTV and field were planned as shown in Figure 2.1. The
single field was treated with the lowest energy whose 90% dose surface (R90) could sufficiently
cover the PTV, assuming continuous energy spacing and scanned electron beams.
For Plan 5, Patient Set 2, the PTVs and fields were created as shown in Figure 2.3. This
plan was developed using the same methods as detailed in Plan 3 with the exception that Therac
20 scanned beams with continuous beam energies rather than Elekta scattered beams with
continuous energy were assumed available and used. That is, the lower field was planned with the
minimum energy whose 90% dose surface (R90) could sufficiently cover the lower PTV, and the
upper field was treated with the minimum energy whose 90% dose surface (R90) could sufficiently
cover the upper PTV.
The parameters for each plan for Patient Set 1 are summarized in Table 2.4. The parameters
for each plan for Patient Set 2 are summarized in Table 2.5.
Table 2.4. Summary of energy availability for each of the four plans for patients in Patient Set 1.
See geometry for plans in Figure 2.1.
Plan

Energy Spacing

Beam Flattening

1
2
3
4
5

Discrete
N/A
Continuous
Discrete
Continuous

Scattered
N/A
Scattered
Scanned
Scanned

Table 2.5. Summary of energy availability for each of the five plans for each patient in Patient Set
2. See geometry for plans 1,2 and 4 in Figure 2.2.
Plan
1
2
3
4
5

Energy Spacing:
Lower PTV
Discrete
Discrete
Continuous
Discrete
Continuous

Energy Spacing:
Upper PTV
Discrete
Continuous
Continuous
Discrete
Continuous
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Beam Flattening
Scattered
Scattered
Scattered
Scanned
Scanned

2.1.7. Design of Bolus and Intensity Modulation for IM-BECT Patient Plans
Bolus and intensity modulations for each field were designed using a research version of
p.d, which included intensity modulation.42 Each bolus was designed using a set of operators from
Low et al.38 that were clinically available and manually optimized to fulfill the design goals of
circumscribing the PTV with the 90% dose surface. Intensity modulation was designed to improve
dose homogeneity in the PTV. Dose calculations in p.d were performed using a 3-dimentional
implementation of the pencil beam redefinition algorithm (PBRA)45–47 with intensity
modulation.34
Operators to create the bolus fall into three categories: bolus creation operators, bolus
modification operators, and bolus extension operators. A description of these operators can be
found in Appendix A. For a specific patient, the sequence of bolus operators for each field are
identical for each plan. The operators used for each patient in Patient Set 1 are almost identical,
with slight variation. Likewise, the operators used for each patient in Patient Set 2 are almost
identical, with slight variation. The operator sequences for Patient Set 1 and Patient Set 2 are listed
in Table 2.6 and Table 2.7, respectively.
Table 2.6. Summary of bolus design operator sequences for Patient Set 1. See Appendix A for
explanation of operators.
Number

PTV Field

1
2
3
4
5
6
7
8
9
10

Create (1.5 cm)
Truncate
Smooth (1,1)
IM (1.1)
Isodose shift (90%)
Smooth (1,1)
Specified shift (-0.2 cm)
Isodose shift (90%)
Smooth (1,0.5)
IM (1.0)
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Table 2.7. Summary of bolus design operator sequences for Patient Set 2. See Appendix A for
explanation of operators.
Number

Lower Field

Upper Field (shifted +Δ)

Upper Field (shifted -Δ)

1
2
3
4
5
6
7
8
9
10

Create (1.5 cm)
Truncate
Smooth (1,1)
IM (1.1)
Isodose shift (90%)
Smooth (1,1)
Specified shift (-0.2 cm)
Isodose shift
Smooth (1,0.5)
IM (1.0)

Create (0.75 cm)
Truncate
Smooth (1,1)
Isodose shift (90%)
Smooth (1,1)
IM (1.1)

Create (0.75 mm)
Truncate
Smooth (1,1)
Specified Shift (-0.8 cm)

For the lower PTV of plans in Patient Set 2, a bolus is created with an inner margin of 1.5 cm
(border between the outer portion of bolus created and outer edge of PTV). Then the truncation
operator was used to minimize the height of the rim of the bolus outside the treatment area, as to
avoid collision between the electron applicator and bolus. The creation operator creates height
irregularities in the bolus surface since the distal surface of the PTV is not smooth, potentially
causing hot and cold spots in the PTV. So, the next step used a smoothing operator to reduce
surface irregularities on the proximal side of the bolus. Intensity modulation further reduced the
hot and cold spots in the PTV. Next, an isodose shift was used to shift the 90% isodose surface
towards the distal PTV surface. The isodose shift operator is a one-dimensional operator, which
means it only considers the difference between the physical distal target depth and the 90% dose
line along each fan line diverging from the source. However, because electrons scatter laterally,
multiple applications of the isodose shift operator were needed for larger targets. Following each
isodose shift operator, the smoothing operator was applied to reduce the hot and cold hots in the
PTV. Following the first isodose shift –smoothing operator sequence, to better visualize PTV
coverage, a specified shift of 0.2 cm was used to shift the 90% dose surface towards the distal
32

surface of the PTV (though this step does not influence the final bolus design). The final steps
were isodose shift, smooth, and intensity modulation to improve the homogeneity of the dose
distribution. This was the baseline set of operators used for all patients in Patient Set 1. However,
this baseline was adjusted on a patient by patient basis to achieve more optimal bolus. For plans
in Patient Set 2, the bolus design operator sequence for the lower field was identical to the sequence
used for Patient Set 1.
2.1.8. Normalization and Summation of Dose
Dose was normalized in p.d for each field such that 100% corresponded to the given dose.
Given dose is defined as the maximum central axis dose (Dmax) in a water phantom at the planned
SSD for the rectangular field with least area that circumscribes the treatment field. The SSD is the
distance from a point 100 cm upstream of isocenter (nominal source location) to the surface of the
bolus along central axis of the beam. Because central axis was in the abutment region for our
beams in Patient Set 2, its SSD was not necessarily representative of that at the center of the field;
therefore, this required that the dose be renormalized so that the mean value of the dose along the
depth of maximum dose was 100%. This was achieved visually by achieving intermittent islands
of the 100% isodose lines in the transverse plane near the field center. These normalization factors
ranged from 0.97 to 1.03 for all twenty plans generated in Patient Set 2. Similar normalization was
used for plans in Patient Set 1 and ranged from 0.99 to 1.01.
After finalizing the beams in p.d for each of the plans for each patient, the dose distributions
for each plan were exported to MIM for summation and conversion from percent dose to dose in
Gy. For Patient Set 2, the composite percent dose distribution equaled the percent dose distribution
for the lower field plus the sum of 50% of the percent dose distributions (±Δ) for the upper fields
(see Figure 2.5), i.e. equal weighting given to both the + Δ and – Δ fields. Percent doses were
converted to dose by prescribing 50 Gy to the 90% contour, i.e. multiplying all values by (50
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Gy/90%). The summed dose distributions for both Patient Set 1 and Patient Set 2 are shown in the
isodose distributions in Appendix B, where 100%=55.5 Gy. The isodose distributions were also
created in MIM.
Finally, for comparing dose distributions for each plan of a single patient, each plan’s
composite dose distribution was scaled relative to that of Plan 1, so all had the same PTV D50, that
is the same dose value for 50% PTV coverage. This scaling was chosen because Plan 1 is the
currently clinically available planning strategy; however, because D50 values of all plans were
within a few percent, this scaling had little impact on the results and conclusions.
2.2. Aim 2—Physical and Biological Dose Metrics for Plans
2.2.1. Dose and Biological Metrics
The cumulative DVHs for the heart, lungs, and PTV were extracted from MIM and
imported to MATLAB, where an in-house script was used to determine the following dose and
biological metrics.
(1) PTV Metrics:
a. D97%-Dose given to 97% of PTV volume
b. Dmax-maximum dose to PTV
c. Dmean-mean dose to PTV
d. V47.5 Gy-volume of PTV receiving 47.5 Gy (95% of 50 Gy prescription)
(2) Heart Metrics:
a. Dmin-minimum dose to heart
b. Dmax-maximum dose to heart
c. Dmean-mean dose to heart
d. V22.5 Gy-volume of heart receiving 22.5 Gy
e. V30 Gy-volume of heart receiving 30 Gy
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f. NTCP-normal tissue complication probability
(3) Lung Metrics:
a. Dmin-minimum dose to lungs
b. Dmax-maximum dose to lungs
c. Dmean-mean dose to lungs
d. V20 Gy-volume of heart receiving 30 Gy
e. NTCP-normal tissue complication probability
f. SCCPlin-Secondary cancer complication probability, linear model
g. SCCPlin-exp-Secondary cancer complication probability, linear-exponential
model
2.2.2. NTCP-Lungs
NTCP values for the lungs were calculated using the Lyman-Kutcher-Burman (LBK)
model.48,
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The endpoint, which was used in the present study, was grade two radiation

pneumonitis or higher, whose model follows:
𝑁𝑇𝐶𝑃 =

−𝑥
𝑡
2
𝑒
∫
√2𝜋 −∞

1

2

𝑑𝑥,

where
𝑡=

𝐸𝑈𝐷−𝑇𝐷50
𝑚∗𝑇𝐷50

,

and
1
𝑛

𝐸𝑈𝐷 = (∑𝑖 𝐷𝑖

𝑛
𝑉𝑖
𝑉𝑡𝑜𝑡

) .

The definitions and values of the various parameters are found in Table 2.8.
.
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Table 2.8. Parameters for computing lung NTCP (from Seppenwoolde et al., 200348)
Parameter
Definition/ Value
𝐷𝑖
dose per fraction to the sub-volume 𝑖
𝑉𝑖
volume irradiated to dose 𝐷𝑖
total volume of lung
𝑉𝑡𝑜𝑡
Slope of the dose-response curve, 0.37
𝑚
Dose from a non-uniform dose distribution that results in
𝐸𝑈𝐷
the same NTCP as a non-uniform dose distribution
Dose that would cause a 50% risk of complication if
𝑇𝐷50
given uniformly, 30.8 Gy
0.99
𝑛

2.2.3. NTCP-Heart
The NTCP for the whole heart was calculated using Kallman’s relative seriality model,
which takes into account both the parallel and serial arrangements of functional subunits within
the heart.50 When finding the NTCP, cardiac mortality was used as the endpoint, i.e.
1

𝑁𝑇𝐶𝑃 = {1 − ∏𝑖 (1 − 𝑃(𝐷𝑖 )𝑠 )𝑉𝑖 } 𝑠 ,
where

−𝑒

𝑃(𝐷𝑖 ) = 2

𝐷
𝑒𝛾(1− 𝑖 )
𝐷50

.

The definitions and values of the various parameters are found in Table 2.9.
Table 2.9. Parameters for computing heart NTCP (from Gagliardi et al., 200110)
Parameter
Definition/ Value
𝐷𝑖
dose to the sub-volume 𝑖
𝑉𝑖
volume irradiated to dose 𝐷𝑖
Ratio of serial function subunits to total functional subunits, 1
𝑠
Dose that would cause a 50% risk of complication if given
𝑇𝐷50
uniformly, 52.3 Gy
Maximum relative slope of the dose-response curve, 1.28
𝛾
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2.2.4. SCCP-Lungs
In addition to NTCP, the secondary cancer complication probability (SCCP) was calculated
for the lungs using two different models, the linear dose response model (SCCPlin) and the linearexponential dose response (SCCPlin-exp). Here, the Schneider model51 was used, i.e.
𝑆𝐶𝐶𝑃𝑙 = Inorg 𝑂𝐸𝐷𝑜𝑟𝑔,𝑙𝑖𝑛𝑒𝑎𝑟 ,
where

OEDorg,linear = 𝑉

1

𝑜𝑟𝑔

∑𝑖 𝑉𝑖 𝐷𝑖 ,

and
𝑆𝐶𝐶𝑃𝑙𝑖𝑛−𝑒𝑥𝑝 = Inorg 𝑂𝐸𝐷𝑜𝑟𝑔,𝑙𝑖𝑛𝑒𝑎𝑟−𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙 ,
where

OEDorg,linear−exponential = 𝑉

1

𝑜𝑟𝑔

∑𝑖 𝑉𝑖 𝐷𝑖 𝑒 −𝛼𝐷𝑖 .

The definitions and values of the various parameters are found in Table 2.10.
Table 2.10. Parameters for computing lung SCCP (from Schneider et al., 200551)
Parameter
Definition/ Value
Organ specific cell sterilization parameter, 0.085
𝛼
Gy-1
𝐷𝑖
dose to the sub-volume 𝑖
𝑉𝑖
volume irradiated to dose 𝐷𝑖
Volume to the total organ
𝑉𝑜𝑟𝑔
Dose from a non-uniform dose distribution that
𝑂EDorg
results in the same cancer incidence as a nonuniform dose distribution
Organ specific absolute cancer incidence as a
percentage per gray, representing the lifetime risk
𝐼𝑁𝑜𝑟𝑔
for a residual lifetime expectancy of 50 years,
1.68% per Gy
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Chapter 3. Results
Aim 1 and Aim 2 results are presented together for each of the seven patients studied. The
first section below describes the beams comprising the treatment plans. The second section shows
and compares dose distributions, dose metrics, and biological metrics for multiple plans for each
patient.
3.1. Description of Treatment Plans for Different Electron Beam Technologies
Aim 1 results show the resulting treatment beams and dose distribution for each of the four or
five treatment plans developed for each of the seven patients. Treatment planning results are
described below, partitioned into the two patent data sets. Plans for Patient Set 1 (CW1, CW3,
CW6) required only a single electron field. Plans for Patient Set 2 (CW2, CW4, CW7, CW8)
required two electron fields (upper and lower).
3.1.1. Treatment Planning Beam Parameters (Patient Set 2)
Patient plans were developed in accordance with the methods described above. For Patient Set
1 (CW1, CW3, CW6), the beam parameters for Plans 1-4 are listed in Table 3.1.
Table 3.1. Summary of beam parameters for each patient and plan in Patient Set 1.
Beam
Energy
Energy R90
Gantry
Patient Plan
Type
Spacing
(MeV) (cm)
Angle (°)
1
Scattered Discrete
21.3
6.0
3
Scattered Continuous
19.5
5.7
CW1
130
4
Scanned Discrete
18.4
6.0
5
Scanned Continuous
17.3
5.7

CW3

1
3
4
5

Scattered
Scattered
Scanned
Scanned

Discrete
Continuous
Discrete
Continuous

13.0
12.4
12.2
11.6

4.0
3.8
4.0
3.8

40

CW6

1
3
4
5

Scattered
Scattered
Scanned
Scanned

Discrete
Continuous
Discrete
Continuous

16.2
15.6
15.1
14.5

5.0
4.8
5.0
4.8

45
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For patients in Patient Set 2 (CW2, CW4, CW7, and CW8) the PTVs were partitioned as
illustrated in Figure 2.2 for Plans 1, 2, and 4, and in Figure 2.3 for Plans 3 and 5. The resulting
beam energies (Ep,0), therapeutic ranges (R90), and beam angles of all five plans for each of the
four patients are listed for the lower and upper fields in Table 3.2.
Table 3.2. Summary of beam parameters for each patient and plan in Patient Set 2.
Lower Lower Upper Upper
Beam
Energy
Field
Field
Field
Field
Gantry
Patient Plan
Type
Spacing
E
R90
E
R90
Angle
(MeV) (cm)
(MeV) (cm)
(°)
1
Scattered Discrete
13.0
4.0
16.2
5.0
2
Scattered Discrete
13.0
4.0
15.9
4.9
CW2
3
Scattered Continuous
13.0
4.0
15.9
4.9
38
4
Scanned Discrete
12.2
4.0
15.1
5.0
5
Scanned Continuous
12.2
4.0
14.8
4.9

Δ
(cm)

0.7

CW4

1
2
3
4
5

Scattered
Scattered
Scattered
Scanned
Scanned

Discrete
Discrete
Continuous
Discrete
Continuous

16.2
16.2
16.2
15.1
15.1

5.0
5.0
5.0
5.0
5.0

21.3
21.3
21.3
18.4
18.4

6.0
6.0
6.0
6.0
6.0

150

0.8

CW7

1
2
3
4
5

Scattered
Scattered
Scattered
Scanned
Scanned

Discrete
Discrete
Continuous
Discrete
Continuous

16.2
16.2
16.2
15.1
15.1

5.0
5.0
5.0
5.0
5.0

21.3
21.3
21.3
18.4
18.4

6.0
6.0
6.0
6.0
6.0

50

0.7

CW8

1
2
3
4
5

Scattered
Scattered
Scattered
Scanned
Scanned

Discrete
Discrete
Continuous
Discrete
Continuous

13.0
13.0
11.1
12.2
10.5

4.0
4.0
3.4
4.0
3.4

16.2
15.6
15.6
14.5
14.5

5.0
4.8
4.8
4.8
4.8

40

0.6

Also, for all five plans, the abutment region was managed by feathering the upper beam, as
illustrated in Figure 2.6. A profile of the abutting scheme for CW2 is illustrated in Figure 2.4 and
the resulting profiles for all four patients are plotted in Figure 3.1. They show the dose
heterogeneity being reduced to less than ±6% in the abutment region of the PTV.
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Figure 3.1. Feathering results for all four patients in Patient Set 2. (a) For CW2, Δ=0.7 cm which
results in dose heterogeneities of +/-4%. (b) For CW4, Δ=0.8 cm which results in dose
heterogeneities of +/-5% (c) For CW7, Δ=0.7 cm which results in dose heterogeneities of +/-6%
(d) For CW8, Δ=0.6 cm which results in dose heterogeneities of +/-4%.
For each plan three transverse and one sagittal-coronal oblique planar dose distributions
are plotted over the CT images. Also, for each patient, DVHs for the PTV, heart, and lungs are
plotted for each plan. Using the DVHs, dose and biologic metrics are calculated and compared in
a single table. Dose metrics include: (1) PTV: D97% (Dose given to 97% of PTV volume), Dmax
(maximum dose), Dmean (mean dose), and V47.5 Gy (relative volume of PTV receiving 47.5 Gy, or
95% of the prescribed dose), (2) Heart: Dmin, Dmax, Dmean, V22.5

Gy

(relative volume of heart

receiving 22.5 Gy), and V30 Gy (relative volume of heart receiving 30 Gy), and (3) Lung: Dmin,
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Dmax, Dmean, and V20 Gy (relative volume of lung receiving 20 Gy). Biological dose metrics include:
(1) Heart: NTCP (normal tissue complication probability) and (2) Lung: NTCP, SCCP lin
(secondary cancer complication probability, linear model), SCCPlin-exp (secondary cancer
complication probability, linear-exponential model).
3.2. Dose Distributions, DVHs, Dose Metrics, and Biological Metrics for All Plans for Each
Patient
Results are presented for three patients in Patient Set 1 (CW1, CW3, and CW6) and four
patients in Patient Set 2 (CW2, CW4, CW7, and CW8). Results for Patient Set 1, for which there
are four plans (Plan 1, Plan 3, Plan 4, and Plan 5 as detailed earlier), are shown first because they
required only a single electron beam and are easier to compare and interpret. Results for Patient
Set 2, for which there are five plans (Plan 1, Plan 2, Plan 3, Plan 4, and Plan 5 as detailed earlier),
are shown second, as they required upper and lower fields, the upper having edge feathering, hence
three electron beams. As such, these plans are more complex to compare and interpret.
The trends indicated by the metrics above can be visualized by comparing the isodose plots
for the four plans being compared. The PTV coverage is appreciated by viewing the PTV and the
80% and 90% isodose lines. The heart dose is appreciated by comparing isodose lines in the dose
falloff region, particularly the 40% isodose line that equals approximately 22.5 Gy, with the
anterior heart in the sagittal-coronal oblique and two inferior planes demarcated on the former.
Lung dose is appreciated by comparing isodose lines in the dose falloff region, particularly the
40% isodose line that is just greater than 20 Gy, within the lung (superior to heart) in the sagittalcoronal oblique and the superior plane demarcated on the former. For the remaining comparisons,
the sagittal-coronal oblique plane and the transverse plane through mid-heart will be shown in the
text, and isodose plots for their respective transverse planes through the region superior to the heart
and through the inferior heart are plotted in Appendix B.
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3.2.1. Result for Patient Set 1
Treatment planning results for patients in Patient Set 1 (CW1, CW3, and CW6) are shown
using isodose plots for three transverse planes and one sagittal-coronal oblique plane for Plans 1,
3, 4, and 5. Inspection of these plots shows utilization of continuous rather than discrete energy
beams usually resulted in lower beam energies. Because lower energy beams have a sharper dose
falloff, this usually resulted in less normal tissue dose and lower complication probabilities. Also,
utilization of scanned versus scattered electron beams, which results in sharper dose falloff,
resulted in less normal tissue dose and lower complication probabilities. The combination of the
two effects is greater than either alone and is illustrated by comparing Plan 1 (scattered, discrete
energy beams) and Plan 5 (scanned beam, continuous energy beams), which represent the worst
and best plans, respectively.
3.2.1.1.

Results for Patient CW1

Treatment planning results for CW1 (Patient Set 1) include isodose plots for three
transverse planes and one sagittal-coronal oblique plane for Plans 1, 3, 4, and 5. All such results
are shown in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each
plan are shown in Figure 3.2 to Figure 3.5. DVHs for PTV, heart, and lungs for each of the four
plans were computed and plotted for comparison in Figure 3.6. Dose and biologic metrics
computed from the DVHs are compared in Table 3.3. These results likely have some dependence
on the location of the distal PTV surface, and for CW1 the distance between the distal edge of the
PTV and the distal side of the chest wall (Δt) was 1.3 cm on central axis.
PTV Coverage: Dose plots (Figure 3.2 to Figure 3.5) show that the 90% isodose lines
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be
improved by increasing the lateral margin between the PTV and field edge or by a more realistic
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PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of the scanned
beams are slightly less than those of the scattered beams. Maximum doses are less than 57 Gy
(<103%).
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 21.3
MeV beam) and Plan 4 (scanned, discrete energy 18.4 MeV beam) showed that the scanned
electron beam reduced (1) mean dose to the heart by 2.7 Gy (8.3 to 5.6 Gy) and (2) V20 Gy to the
lung by 3.7% (17.2 to 13.5%). This resulted in reduced (1) NTCPheart by 0.2% (0.4 to 0.1%), (2)
NTCPlungs by 0.01% (0. 02 to 0.01%), and (3) SCCPlin by 3.5% (14.4 to 10.8%).
Comparing Plan 3 (scattered, continuous energy 19.5 MeV beam) and Plan 5 (scanned,
continuous energy 17.3 MeV beam) showed that the scanned electron beam reduced (1) mean dose
to the heart by 2.0 Gy (6.4 to 4.3 Gy) and (2) V20Gy to the lung by 3.4% (14.1 to 10.7%). This
resulted in reduced (1) NTCPheart by 0.1% (0.2 to 0.1%), (2) NTCPlungs by 0.0% (0. 01 to 0.01%),
and (3) SCCPlin by 3.1% (11.7 to 8.7%).
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 1 (scattered,
discrete energy 21.3 MeV beam) with Plan 3 (scattered, continuous energy 19.5 MeV beam)
showed that continuous energy beams reduced (1) mean dose to the heart by 1.9 Gy (8.3 to 6.4
Gy) and (2) V20Gy to the lung by 3.2% (17.2 to 14.1%). This resulted in reduced (1) NTCPheart by
0.2% (0.4 to 0.2%), (2) NTCPlungs by 0.01% (0. 02 to 0.01%), and (3) SCCPlin by 2.6% (14.4% to
11.7%).
Comparing Plan 4 (scanned, discrete energy 18.4 MeV beam) with Plan 5 (scanned,
continuous energy 17.3 MeV beam) showed that continuous energy beams reduced (1) mean dose
to the heart by 1.3 Gy (5.6 to 4.3 Gy) and (2) V20Gy to the lung by 2.8% (13.5 to 10.7%). This
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resulted in reduced (1) NTCPheart by 0.09% (0.14 to 0.05%), (2) NTCPlungs by 0.00% (0. 01 to
0.01%), and (3) SCCPlin by 2.1% (10.8% to 8.7%).
Effect of Scanned, Continuous Energy Beams vs. Scattered, Discrete Energy Beams: The
greatest plan improvement was comparing Plan 1 (scattered, discrete energy 21.3 MeV beam),
current technology, with Plan 5 (scanned, continuous energy 17.3 MeV beam), possible future
technology, which reduced (1) mean dose to the heart by 3.9 Gy (8.3 to 4.3 Gy) and (2) V20Gy to
the lung by 6.5% (17.2 to 10.7%). This resulted in reduced (1) NTCPheart by 0.3% (0.4 to 0.05%),
(2) NTCPlungs by 0.01% (0.02 to 0.01%), and (3) SCCPlin by 5.7% (14.4% to 8.7%).
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Figure 3.2. Sagittal and axial images of CW1, Plan 1. CW1 (Patient Set 1) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.3. Sagittal and axial images of CW1, Plan 3. CW1 (Patient Set 1) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.4. Sagittal and axial images of CW1, Plan 4. CW1 (Patient Set 1) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.5. Sagittal and axial images of CW1, Plan 5. CW1 (Patient Set 1) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.6. Comparison of cumulative DVH plots for CW1 (Patient Set 1) Plans. DVH plots for
PTV, heart, and lung are compared for Plans 1, 3, 4, and 5, as indicated in key.
Table 3.3. Comparison of metrics for CW1 (Patient Set 1) Plans. Dose metrics are shown for PTV,
heart, and lungs. NTCP and SCCP values are shown for heart and lungs.
Plan 1 Plan 3 Plan 4 Plan 5
46.9
46.4
46.2
45.9
D97% (Gy)
96.2
95.3
94.6
94.1
V47.5 Gy (%)
56.6
56.9
56.7
56.7
PTV
Max dose (Gy)
51.9
51.8
51.7
51.7
Mean dose (Gy)
2.2
2.5
2.6
2.8
Std Dev (Gy)

Heart

Lungs

V22.5 Gy (%)
V30 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)

10.4
3.1
1.3
40.9
8.3
8.3
0.4

5.7
0.9
1.1
37.9
6.4
7.2
0.2

4.9
0.8
0.7
38.2
5.6
7.2
0.1

2.3
0.1
0.5
34.1
4.3
6.0
0.1

V20 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)
SCCPlin (%)
SCCPlin-exp (%)

17.2
0.0
47.1
8.6
11.9
0.02
14.4
3.4

14.1
0.0
45.4
7.0
10.7
0.01
11.7
3.0

13.5
0.0
49.0
6.5
10.7
0.01
10.8
2.6

10.7
0.0
43.8
5.2
9.4
0.01
8.7
2.2
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3.2.1.2.

Results for Patient CW3

Treatment planning results for CW3 (Patient Set 1) include isodose plots for three
transverse planes and one sagittal-coronal oblique plane for Plans 1, 3, 4, and 5. All such results
are shown in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each
plan are shown in Figure 3.7 to Figure 3.10. DVHs for PTV, heart, and lungs for each of the four
plans were computed and plotted for comparison in Figure 3.11. Dose and biologic metrics
computed from the DVHs are compared in Table 3.4. These results likely have some dependence
on the location of the distal PTV surface, and for CW3 the distance between the distal edge of the
PTV and the distal side of the chest wall (Δt) was 1.1 cm on central axis.
PTV Coverage: Dose plots (Figure 3.7 to Figure 3.10) show that the 90% isodose lines
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be
improved by increasing the lateral margin between the PTV and field edge or by a more realistic
PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of the scanned
beams are slightly less than those of the scattered beams. Maximum doses are less than 59 Gy
(<106%).
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 13.0
MeV beam) and Plan 4 (scanned, discrete energy 12.2 MeV beam) showed that the scanned
electron beam reduced (1) mean dose to the heart by 0.2 Gy (4.3 to 4.1 Gy) and (2) V20 Gy to the
lung by 1.7% (15.8 to 14.1%). This resulted in reduced (1) NTCPheart by 0.05% (0.1 to 0.05%), (2)
NTCPlungs by 0.00% (0.01 to 0.01%), and (3) SCCPlin by 1.3% (11.8 to 10.5%).
Comparing Plan 3 (scattered, continuous energy 12.4 MeV beam) and Plan 5 (scanned,
continuous energy 11.6 MeV beam) showed that the scanned electron beam reduced (1) mean dose
to the heart by 0.0 Gy (3.7 to 3.7 Gy) and (2) V20Gy to the lung by 2.0% (14.5 to 12.5%). This
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resulted in reduced (1) NTCPheart by 0.03% (0.06 to 0.03%), (2) NTCPlungs by 0.0% (0.1 to 0.1%),
and (3) SCCPlin by 1.3% (10.7 to 9.4%).
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 1 (scattered,
discrete energy 13.0 MeV beam) with Plan 3 (scattered, continuous energy 12.4 MeV beam)
showed that continuous energy beams reduced (1) mean dose to the heart by 0.6 Gy (4.3 to 3.7
Gy) and (2) V20Gy to the lung by 1.4% (15.8 to 14.5%). This resulted in reduced (1) NTCPheart by
0.04% (0.1 to 0.06%), (2) NTCPlungs by 0.00% (0.01 to 0.01%), and (3) SCCPlin by 1.1% (11.8%
to 10.7%).
Comparing Plan 4 (scanned, discrete energy 12.2 MeV beam) with Plan 5 (scanned,
continuous energy 11.6 MeV beam) showed that continuous energy beams reduced (1) mean dose
to the heart by 0.4 Gy (4.1 to 3.7 Gy) and (2) V20Gy to the lung by 1.6% (14.1 to 12.5%). This
resulted in reduced (1) NTCPheart by 0.02% (0.05 to 0.03%), (2) NTCPlungs by 0.0% (0.1 to 0.1%),
and (3) SCCPlin by 1.1% (10.5% to 9.4%).
Effect of Scanned, Continuous Energy Beams vs. Scattered, Discrete Energy Beams: The
greatest plan improvement was comparing Plan 1 (scattered, discrete energy 13.0 MeV beam),
current technology, with Plan 5 (scanned, continuous energy 11.6 MeV beam), possible future
technology. This reduced (1) mean dose to the heart by 0.6 Gy (4.3 to 3.7 Gy) and (2) V20Gy to the
lung by 3.3% (15.8 to 12.5%). This resulted in reduced (1) NTCPheart by 0.07% (0.1 to 0.03%), (2)
NTCPlungs by 0.00% (0.01 to 0.01%), and (3) SCCPlin by 2.4% (11.8% to 9.4%).
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Figure 3.7. Sagittal and axial images of CW3, Plan 1. CW3 (Patient Set 1) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.8. Sagittal and axial images of CW3, Plan 3. CW3 (Patient Set 1) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.9. Sagittal and axial images of CW3, Plan 4. CW3 (Patient Set 1) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.10. Sagittal and axial images of CW3, Plan 5. CW3 (Patient Set 1) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.

55

Figure 3.11. Comparison of cumulative DVH plots for CW3 (Patient Set 1) Plans. DVH plots for
PTV, heart, and lung are compared for Plans 1, 3, 4, and 5, as indicated in key.
Table 3.4. Comparison of metrics for CW3 (Patient Set 1) Plans. Dose metrics are shown for PTV,
heart, and lungs. NTCP and SCCP values are shown for heart and lungs.
Plan 1 Plan 3 Plan 4 Plan 5
45.4
44.9
44.8
44.4
D97% (Gy)
93.2
92.2
91.7
91.0
V47.5 Gy (%)
58.3
58.8
58.6
58.6
PTV
Max dose (Gy)
51.6
51.6
51.6
51.5
Mean dose (Gy)
2.7
2.8
2.9
3.0
Std Dev (Gy)

Heart

V22.5 Gy (%)
V30 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)

3.4
0.5
0.7
36.6
4.3
6.3
0.1

2.5
0.2
0.7
34.1
3.7
5.8
0.1

2.2
0.2
0.0
35.0
4.1
5.4
0.1

1.5
0.0
0.1
32.7
3.7
4.9
0.03

Lungs

V20 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)
SCCPlin (%)
SCCPlin-exp (%)

15.8
0.0
46.7
7.0
11.6
0.0
11.8
2.3

14.5
0.0
46.5
6.4
11.1
0.0
10.7
2.1

14.1
0.0
46.4
6.2
11.0
0.0
10.5
2.1

12.5
0.0
46.3
5.6
10.3
0.0
9.4
2.0
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3.2.1.3.

Results for Patient CW6

Treatment planning results for CW6 (Patient Set 1) include isodose plots for three
transverse planes and one sagittal-coronal oblique plane for Plans 1, 3, 4, and 5. All such results
are shown in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each
plan are shown in Figure 3.12 to Figure 3.15. DVHs for PTV, heart, and lungs for each of the four
plans were computed and plotted for comparison in Figure 3.16. Dose and biologic metrics
computed from the DVHs are compared in Table 3.5. These results likely have some dependence
on the location of the distal PTV surface, and for CW6 the distance between the distal edge of the
PTV and the distal side of the chest wall (Δt) was 0.4 cm on central axis.
PTV Coverage: Dose plots (Figure 3.12 to Figure 3.15) show that the 90% isodose lines
closely cover the distal PTV surface, or in some locations, the 80% isodose line due to the large
variation of thickness of the PTV in the lateral direction. Most evident at the lateral edges of the
PTV, coverage could be improved by increasing the lateral margin between the PTV and field
edge or by a more realistic PTV (smoother edges). The PTV DVHs are similar for all plans; V47.
5Gy

values of the scanned beams are slightly less than those of the scattered beams. Maximum

doses are less than 59 Gy (<106%).
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy 16.2
MeV beam) and Plan 4 (scanned, discrete energy 15.1 MeV beam) showed that the scanned
electron beam reduced (1) mean dose to the heart by 1.9 Gy (8.3 to 6.4 Gy) and (2) V20 Gy to the
lung by 2.0% (19.8 to 17.8%). This resulted in reduced (1) NTCPheart by 0.2% (0.7 to 0.5%), (2)
NTCPlungs by 0.01% (0.03 to 0.02%), and (3) SCCPlin by 2.2% (15.9 to 13.7%).
Comparing Plan 3 (scattered, continuous energy 15.6 MeV beam) and Plan 5 (scanned,
continuous energy 14.5 MeV beam) showed that the scanned electron beam reduced (1) mean dose
to the heart by 2.0 Gy (7.8 to 5.8 Gy) and (2) V20Gy to the lung by 2.4% (19.1 to 16.8%). This
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resulted in reduced (1) NTCPheart by 0.2% (0.6 to 0.4%), (2) NTCPlungs by 0.00% (0.02 to 0.02%),
and (3) SCCPlin by 2.5% (15.3 to 12.8%).
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 1 (scattered,
discrete energy 16.2 MeV beam) with Plan 3 (scattered, continuous energy 15.6 MeV beam)
showed that continuous energy beams reduced (1) mean dose to the heart by 0.5 Gy (8.3 to 7.8
Gy) and (2) V20Gy to the lung by 0.7% (19.8 to 19.1%). This resulted in reduced (1) NTCPheart by
0.1% (0.7 to 0.6%), (2) NTCPlungs by 0.01% (0.03 to 0.02%), and (3) SCCPlin by 0.6% (15.9% to
15.3%).
Comparing Plan 4 (scanned, discrete energy 15.1 MeV beam) with Plan 5 (scanned,
continuous energy 14.5 MeV beam) showed that continuous energy beams reduced (1) mean dose
to the heart by 0.7 Gy (6.4 to 5.8 Gy) and (2) V20Gy to the lung by 1.0% (17.8 to 16.8%). This
resulted in reduced (1) NTCPheart by 0.09% (0.5 to 0.4%), (2) NTCPlungs by 0.00% (0.02 to 0.02%),
and (3) SCCPlin by 0.9% (13.7 to 12.8%).
Effect of Scanned, Continuous Energy Beams vs. Scattered, Discrete Energy Beams: The
greatest plan improvement was comparing Plan 1 (scattered, discrete energy 16.2 MeV beam),
current technology, with Plan 5 (scanned, continuous energy 14.5 MeV beam), possible future
technology. This reduced (1) mean dose to the heart by 2.5 Gy (8.3 to 5.8 Gy) and (2) V20Gy to the
lung by 3.0% (19.8 to 16.8%). This resulted in reduced (1) NTCPheart by 0.3% (0.7 to 0.4%), (2)
NTCPlungs by 0.01% (0.03 to 0.02%), and (3) SCCPlin by 3.1% (15.9% to 12.8%).

58

Figure 3.12. Sagittal and axial images of CW6, Plan 1. CW6 (Patient Set 1) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.13. Sagittal and axial images of CW6, Plan 3. CW6 (Patient Set 1) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.14. Sagittal and axial images of CW6, Plan 4. CW6 (Patient Set 1) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.15. Sagittal and axial images of CW6, Plan 5. CW6 (Patient Set 1) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.16. Comparison of cumulative DVH plots for CW6 (Patient Set 1) Plans. DVH plots for
PTV, heart, and lung are compared for Plans 1, 3, 4, and 5, as indicated in key.
Table 3.5. Comparison of metrics for CW6 (Patient Set 1) Plans. Dose metrics are shown for PTV,
heart, and lungs. NTCP and SCCP values are shown for heart and lungs.
Plan 1 Plan 3 Plan 4 Plan 5
46.7
46.4
46.2
45.8
D97% (Gy)
95.0
94.5
93.5
92.7
V47.5 Gy (%)
57.8
58.2
57.9
58.6
PTV
Max dose (Gy)
52.2
52.2
52.1
52.0
Mean dose (Gy)
2.6
2.6
2.8
2.8
Std Dev (Gy)

Heart

V22.5 Gy (%)
V30 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)

12.7
6.4
0.9
46.2
8.3
10.3
0.7

11.7
5.7
0.8
45.8
7.8
10.0
0.6

9.5
4.2
0.2
45.6
6.4
9.4
0.5

8.2
3.4
0.0
44.3
5.8
9.0
0.4

Lungs

V20 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)
SCCPlin (%)
SCCPlin-exp (%)

19.8
0.0
50.4
9.5
13.5
0.03
15.9
3.0

19.1
0.0
50.0
9.1
13.4
0.02
15.3
2.8

17.8
0.0
49.9
8.2
13.2
0.02
13.7
2.3

16.8
0.0
49.3
7.6
12.8
0.02
12.8
12.8
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3.2.2. Results for Patient Set 2
Plan comparisons for Patient Set 2 (CW2, CW4, CW7, and CW8) were more
complex that those of Patient Set 1 because this study had no criteria for optimizing the location
of the abutting edge of the lower field (greatest impact on heart dose) and upper fields (greatest
impact on lung dose). For the scattered beams, Plan 1 placed the abutting edge as far superior as
allowed for the minimum energy that could be used for the lower field. This likely represents the
best plan that could be created when using scattered, discrete energy beams, which is the only plan
deliverable with currently available radiotherapy accelerator technology. Plan 2 uses the same
lower field as Plan 1, but assumes scattered, continuous energy beams for the upper field. Plan 3,
which assumes scattered, continuous energy beams for both the lower and upper fields, places the
edge at the superior aspect of the heart. The optimal location of the abutting edge is somewhere
between that of Plans 2 and 3; however, no effort was made to determine that location in the current
study. For such optimization, the tradeoff between heart dose and lung dose must be specified.
Plans 4 and 5 used scanned, discrete energy beams and scanned, continuous energy beams,
respectively with the same field placements as Plans 1 and 3, respectively. Therefore, the impact
of scanned beams was evaluated comparing Plans 1 with Plan 4 for discrete beam energies and
Plan 3 with Plan 5 for continuous beam energies.
The impact of continuous energy beams was evaluated comparing Plan 1 with Plan 2 or
Plan 3 (used scattered beams), whichever best, and Plan 4 with Plan 5 (used scanned beams). The
latter comparison is not optimal, as abutting edges of Plan 4 and Plan 5 were different, and a Plan
6 with the same edge location as Plan 4 might have been useful.
As results will show, placing the abutting edge at the superior aspect of the heart (Plans 3
and 5) resulted in higher lung doses, due to the upper field being larger than the other beam
arrangement, and higher heart doses, apparently due to the wider penumbra of the upper, higher
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energy field. The effect of this will be seen in the patient results to follow. Therefore, it is not
meaningful to compare any two plans to demonstrate the benefit of using scanned, continuous
energy beams overs scattered, discrete energy beams as was done for Patient Set 1.
3.2.2.1.

Results for Patient CW2

Treatment planning results for CW2 (Patient Set 2) include isodose plots for three
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. All such results are shown
in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each plan are
shown in Figure 3.17 to Figure 3.21. DVHs for PTV, heart, and lungs for each of the five dose
plans were computed and plotted for comparison in Figure 3.22. Dose and biologic metrics
computed from these DVHs are compared in Table 3.6. These results likely have some dependence
on the location of the distal PTV surface, and the CW2 distance between the distal edge of the
PTV and the distal side of the chest wall (Δt) was 1.2 cm on central axis.
PTV Coverage: Dose plots (Figure 3.17 to Figure 3.21) show that the 90% isodose lines
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be
improved by increasing the lateral margin between the PTV and field edge or by a more realistic
PTV (smoother edges). The PTV DVHs are similar for all plans; however, V47.5 Gy values of Plans
3 and 5, which have the field arrangement used for the continuous energy beam (see Figure 2.3)
are slightly greater than those of Plans 1, 2, and 4, which use a different field arrangement (see
Figure 2.2). Although maximum doses are as large as approximately 65 Gy (117%), no significant
volume receives more than 61 Gy (110%).
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy
beams, upper 16.2 MeV and lower 13.0 MeV) and Plan 4 (scanned, discrete energy beams, upper
15.1 MeV and lower 12.2 MeV) showed that the scanned electron beam reduced (1) mean dose to
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the heart by 0.7 Gy (4.6 to 3.9 Gy) and (2) V20 Gy to the lungs by 2.5% (13.0 to 10.5%). This
resulted in reduced (1) NTCPheart by 0.5% (0.9 to 0.40%), (2) NTCPlungs by 0.3% (1.4 to 1.0%),
and (3) SCCPlin by 2.2% (11.0 to 8.9%).
Comparing Plan 3 (scattered, continuous energy beams, upper 15.9 MeV and lower 13.0
MeV) and Plan 5 (scanned, continuous energy beams, upper 14.8 MeV and lower 12.2 MeV)
showed that the scanned electron beam reduced (1) mean dose to the heart by 2.6 Gy (8.1 to 5.5
Gy) and (2) V20Gy to the lungs by 3.6% (22.2 to 18.6%). This resulted in reduced (1) NTCPheart by
0.2% (0.3 to 0.1%), (2) NTCPlungs by 1.2% (3.5 to 2.3%), and (3) SCCPlin by 3.5% (18.4 to 14.9%).
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 2 (scattered,
continuous energy beams, upper 15.9 MeV and discrete energy lower 13.0 MeV beam) with Plan
3 (scattered, continuous energy beams, upper 15.9 MeV and lower 13.0 MeV) showed Plan 2 to
have lower heart and lung dose because of the beam arrangements. Therefore, Plan 2, compared
to Plan 1 (scattered, discrete energy beams, upper 16.2 MeV and lower 13.0 MeV), shows (1)
similar mean dose to the heart (4.6 Gy) and (2) V20 Gy to the lungs reduced slightly by 0.2% (13.0
to 12.8%). This resulted in (1) equal NTCPheart of 0.9%, (2) NTCPlungs reduced slightly by 0.03%
(1.4 to 1.4%), and (3) SCCPlin reduced slightly by 0.2% (11.0% to 10.8%).
Comparing Plan 4 (scanned, discrete energy beams, upper 15.1 MeV and lower 12.2 MeV)
with Plan 5 (scanned, continuous energy beams, upper 14.8 MeV and lower 12.2 MeV) showed
no advantage to continuous energy. Rather, it showed the advantage of the field arrangement for
Plan 4, as Plan 5 increased (1) mean dose to the heart by 1.6 Gy (3.9 to 5.5 Gy) and (2) V20 Gy to
the lung by 8.2% (10.5 to 18.6%). In addition, this resulted in increased (1) NTCPheart by 0.3%
(0.40 to 0.1%), (2) NTCPlungs by 1.3% (1.0 to 2.3%), and (3) SCCPlin by 6.0% (8.9% to 14.9%).
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Summary: Results showed that scanned electron beams modestly reduced heart and lung
dose and their biologic effect. NTCP changes were not likely significant because of their already
low value for scattered beams, which was attributed to CW2 PTV requiring only 12.50.5 MeV
(over heart) and 15.50.7 MeV (over lung) beams. Continuous energy beams showed insignificant
improvement over discrete energy beams, because the discrete energies available were already
near optimal. More significant was the location of the edge of abutting beams, indicating the need
for optimizing its location in future studies.
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Figure 3.17. Sagittal and axial images of CW2, Plan 1. CW2 (Patient Set 2) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
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Figure 3.18. Sagittal and axial images of CW2, Plan 2. CW2 (Patient Set 2) was planned using
scattered electron beams, discrete energy spacing (lower field), and continuous energy spacing
(upper field). (a) Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in
figure (b)’s transverse plane; (b) Dose plan in transverse plane passing through central heart region,
demarcated by red line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus
is shaded light blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.19. Sagittal and axial images of CW2, Plan 3. CW2 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
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Figure 3.20. Sagittal and axial images of CW2, Plan 4. CW2 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
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Figure 3.21. Sagittal and axial images of CW2, Plan 5. CW2 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.22. Comparison of cumulative DVH plots for CW2 (Patient Set 2) Plans. DVH plots for
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key.
Table 3.6. Comparison of metrics for CW2 (Patient Set 2) Plans. Dose metrics are shown for PTV,
heart, and lungs. NTCP and SCCP values are shown for heart and lungs.
Plan 1 Plan 2 Plan 3 Plan 4 Plan 5
46.9
46.9
48.2
46.3
47.4
D97% (Gy)
96.3
96.3
98.4
96.0
97.6
V47.5 Gy (%)
64.5
64.2
67.1
63.0
66.4
PTV
Max dose (Gy)
54.0
54.0
54.6
54.0
54.4
Mean dose (Gy)
3.1
3.1
2.9
3.1
2.9
Std Dev (Gy)

Heart

Lungs

V22.5 Gy (%)
V30 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)

3.1
0.4
0.7
38.0
4.6
5.8
0.9

3.1
0.4
0.7
38.0
4.6
5.8
0.9

8.4
2.8
2.0
43.4
8.1
8.0
0.3

1.7
0.1
0.1
36.1
3.9
4.9
0.4

4.6
0.8
0.7
39.2
5.5
6.9
0.1

V20 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)
SCCPlin (%)
SCCPlin-exp (%)

13.0
0.0
47.8
6.6
10.1
1.4
11.0
2.9

12.8
0.0
47.7
6.5
10.1
1.4
10.8
2.8

22.2
0.0
50.9
10.9
13.3
3.5
18.4
3.8

10.5
0.0
46.5
5.3
9.2
1.0
8.9
2.3

18.6
0.0
50.2
8.8
12.6
2.3
14.9
3.0
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3.2.2.2.

Results for Patient CW4

Treatment planning results for CW4 (Patient Set 2) include isodose plots for three
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. However, Plans 1 and 2
are identical as the optimal, continuous energy for the upper field was the same as the discrete
energy used in Plan 1. All such results are shown in Appendix B, and one sagittal-coronal oblique
plane and one transverse plane for each plan are shown Figure 3.23 to Figure 3.26. DVHs for PTV,
heart, and lungs for each of the five dose plans were computed and plotted for comparison in Figure
3.27. Dose and biologic metrics computed from these DVHs are compared in Table 3.7. These
results likely have some dependence on the location of the distal PTV surface, and the CW4
distance between the distal edge of the PTV and the distal side of the chest wall (Δt) was 1.9 cm
on central axis.
PTV Coverage: Dose plots (Figure 3.23 to Figure 3.26) show that the 90% isodose lines
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be
improved by increasing the lateral margin between the PTV and field edge or by a more realistic
PTV (smoother edges). The PTV DVHs are similar for all plans; however, V47.5 Gy values of Plans
1 and 2 (≈95%), which use scattered beams are greater than those for Plans 3 and 5 (≈91%). This
is possibly due to the different dose distributions given by the scanned and scattered beams, as
well as the different field arrangements. Although maximum doses are as large as approximately
66 Gy (119%), no significant volume receives more than 59 Gy (105%).
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy
beams, upper 21.3 MeV and lower 16.2 MeV) and Plan 4 (scanned, discrete energy beams, upper
18.4 MeV and lower 15.1 MeV) showed that the scanned electron beam reduced (1) mean dose to
the heart by 1.4 Gy (3.8 to 2.4 Gy) and (2) V20 Gy to the lungs by 2.5% (11.8 to 9.2%). This
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resulted in insignificant reduction to (1) NTCPheart by 0.01% (0.01 to 0.00%) and (2) NTCPlungs by
0.00% (0.01 to 0.01%), because of their already low values, and reduction to (3) SCCPlin by 2.8%
(10.9 to 8.1%).
Comparing Plan 3 (scattered, continuous energy beams, upper 21.3 MeV and lower 16.2
MeV) and Plan 5 (scanned, continuous energy beams, upper 18.4 MeV and lower 15.1 MeV)
showed that the scanned electron beam reduced (1) mean dose to the heart by 1.2 Gy (3.6 to 2.4
Gy) and (2) V20Gy to the lung by 1.6% (11.7 to 10.1%). This resulted in insignificant reduction to
(1) NTCPheart by 0.01% (0.01 to 0.00%) and (2) NTCPlungs by 0.00% (0.01 to 0.01%), because of
their already low values, and reduction to (3) SCCPlin by 1.9% (10.7 to 8.8%).
Effect of Continuous vs. Discrete Beam Energies: For Plan 2, the optimal continuous
energy for the upper beam was identical to the discrete energy used in Plan 1. Thus, Plan 1 and
Plan 2 are identical. The optimal continuous energy for all beams in Plans 2, 3, and 5 were the
same as the discrete energies for the beams in Plans 1 and 4. Thus, no conclusions can be drawn
about the effect of using continuous vs. discrete energy spacing for this patient, CW4.
Impact of Location of Edges of Abutting Beams: Comparing Plan 2 (scattered, continuous
energy beams, upper 21.3 MeV and discrete energy lower 16.2 MeV beam) with Plan 3 (scattered,
continuous energy beams, upper 21.3 MeV and lower 16.2 MeV) showed Plan 2 to have essentially
identical heart and lung dose due to the boundaries given to the upper and lower PTVs, but slightly
lower SCCPlin. Therefore, Plan 3, compared to Plan 1 (scattered, discrete energy beams, upper 21.3
MeV and lower 16.2 MeV), shows small reduced (1) mean dose to the heart by 0.2 Gy (3.8 to 3.6
Gy) and (2) V20 Gy to the lung reduced slightly by 0.08% (11.8 to 11.7%). This resulted in (1) equal
NTCPheart of 0.01%, (2) equal NTCPlungs 0.01%, and (3) SCCPlin reduced slightly by 0.2% (10.9%
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to 10.7%). These differences are due to the location of the edge of abutting beams, as the energies
used for each comparison are identical.
Comparing Plan 4 (scanned, discrete energy beams, upper 18.4 MeV and lower 15.1 MeV)
with Plan 5 (scanned, continuous energy beams, upper 18.4 MeV and lower 15.1 MeV) showed
no advantage to continuous energy; none would be expected since the selected discrete energies
were the same as continuous ones. Rather, it showed the advantage of the field arrangement
(abutment location) for Plan 4, as Plan 5 (1) had equal mean dose to the heart (2.4 Gy), but (2)
increased V20 Gy to the lung by 0.9% (9.2 to 10.1%). This resulted in (1) identical NTCPheart of
0.00%, (2) identical NTCPlungs of 0.01%, and (3) increased SCCPlin by 0.7% (8.1% to 8.8%).
Summary: Results showed that scanned electron beams slightly reduced heart and lung
dose and their biologic effect. NTCP changes were not likely significant because of their already
low value for scattered beams, which was attributed to the larger separation (1.9 cm) between the
PTV and distal chest wall. Improvement of continuous energy beams over discrete energy beams
was unable to be evaluated for CW4. Also, the location of the edge of abutting beams had little
effect, due to the already low normal tissue doses and biologic effects. This is likely due to the
larger separation between the distal PTV surface and the distal chest wall on central axis.
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Figure 3.23. Sagittal and axial images of CW4, identical Plans 1 and 2. CW4 (Patient Set 2) was
planned using scattered electron beams and discrete energy spacing for Plan 1 and scattered beams
with discrete energy spacing (lower field) and continuous energy spacing (upper field) for Plan 2.
(a) Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s
transverse plane; (b) Dose plan in transverse plane passing through central heart region,
demarcated by red line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus
is shaded light blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.24. Sagittal and axial images of CW4, Plan 3. CW4 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
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Figure 3.25. Sagittal and axial images of CW4, Plan 4. CW4 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
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Figure 3.26. Sagittal and axial images of CW4, Plan 5. CW4 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
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Figure 3.27. Comparison of cumulative DVH plots for CW4 (Patient Set 2) Plans. DVH plots for
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key. Note that Plans
1 and 2 are identical for CW4.
Table 3.7. Comparison of metrics for CW4 (Patient Set 2) Plans. Dose metrics are shown for PTV,
heart, and lungs. NTCP and SCCP values are shown for heart and lungs. Note that Plans 1 and 2
are identical for CW4.
Plan 1 Plan 2 Plan 3 Plan 4 Plan 5
45.7
45.7
44.3
43.2
43.5
D97% (Gy)
94.75 94.75 91.63 91.87 91.02
V47.5 Gy (%)
63.06 63.06 66.55 65.98 64.79
PTV
Max dose (Gy)
53.83 53.83 53.50 53.48 53.48
Mean dose (Gy)
0.24
0.24
0.34
0.04
0.4
Std Dev (Gy)

Heart

Lungs

V22.5 Gy (%)
V30 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)

0.4
0.0
1.2
32.7
3.8
3.6
0.01

0.4
0.0
1.2
32.7
3.8
3.6
0.01

0.6
0.0
0.6
33.3
3.6
3.9
0.01

0.1
0.1
0.5
27.9
2.4
3.2
0.0

0.1
0.2
0.1
28.6
2.4
3.3
0.0

V20 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)
SCCPlin (%)
SCCPlin-exp (%)

11.8
0.0
48.1
6.5
9.6
0.01
10.9
3.2

11.8
0.0
48.1
6.5
9.6
0.01
10.9
3.2

11.7
0.0
48.8
6.4
9.8
0.01
10.7
3.1

9.2
0.0
46.1
4.8
8.7
0.01
8.1
2.3

10.1
0.0
50.4
5.2
9.5
0.01
8.8
2.3
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3.2.2.3.

Results for Patient CW7

Treatment planning results for CW7 (Patient Set 2) include isodose plots for three
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. However, Plans 1 and 2
are identical as the optimal, continuous energy for the upper field was the same as the discrete
energy used in Plan 1. All such results are shown in Appendix B, and one sagittal-coronal oblique
plane and one transverse plane for each plan are shown in Figure 3.28 to Figure 3.31. DVHs for
PTV, heart, and lungs for each of the five dose plans were computed and plotted for comparison
in Figure 3.32. Dose and biologic metrics computed from these DVHs are compared in Table 3.8.
These results likely have some dependence on the location of the distal PTV surface, and the CW7
distance between the distal edge of the PTV and the distal side of the chest wall (Δt) was 0.9 cm
on central axis.
PTV Coverage: Dose plots (Figure 3.28 to Figure 3.31) show that the 90% isodose lines
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be
improved by increasing the lateral margin between the PTV and field edge or by a more realistic
PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of Plans 3 and 5,
which have the field arrangement used for the continuous energy beams (see Figure 2.3) are
slightly greater than those of Plans 1, 2, and 4, which use a different field arrangement (see Figure
2.2). Although maximum doses are as large as approximately 69 Gy (124%), no significant volume
receives more than 62 Gy (112%).
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy
beams, upper 21.3 MeV and lower 16.2 MeV) and Plan 4 (scanned, discrete energy beams, upper
18.4 MeV and lower 15.1 MeV) showed that the scanned electron beam reduced (1) mean dose to
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the heart by 2.6 Gy (9.6 to 7.0 Gy) and (2) V20

Gy

to the lungs by 4.1% (20.6 to 16.5%). This

resulted in reduced (1) NTCPheart by 0.2% (0.5 to 0.3%), (2) NTCPlungs by 0.02% (0.04 to 0.02%),
and (3) SCCPlin by 4.6% (18.2 to 13.7%).
Comparing Plan 3 (scattered, continuous energy beams, upper 21.3 MeV and lower 16.2
MeV) and Plan 5 (scanned, continuous energy beams, upper 18.4 MeV and lower 15.1 MeV)
showed that the scanned electron beam reduced (1) mean dose to the heart by 2.2 Gy (9.7 to 7.5
Gy) and (2) V20 Gy to the lungs by 1.2% (17.7 to 16.5%). This resulted in reduced (1) NTCPheart by
0.2% (0.6 to 0.4%), (2) NTCPlungs by 0.01% (0.03 to 0.02), and (3) SCCPlin by 1.8% (15.9 to
14.1%).
Effect of Continuous vs. Discrete Beam Energies: For Plan 2, the optimal continuous
energy for the upper beam was identical to the discrete energy used in Plan 1. Thus, Plan 1 and
Plan 2 are identical. The optimal continuous energy for all beams in Plans 2,3, and 5 were the same
as the discrete energies for the beams in Plans 1 and 4. Thus, no conclusions can be drawn about
the effect of using continuous vs. discrete energy spacing for this patient, CW7.
Impact of Location of Edges of Abutting Beams: Comparing Plan 2 (scattered, continuous
energy beams, upper 21.3 MeV and discrete energy lower 16.2 MeV beam) with Plan 3 (scattered,
continuous energy beams, upper 21.3 MeV and lower 16.2 MeV) showed (1) mean dose to the
heart by 0.0 Gy (9.7 to 9.7 Gy) and (2) V20 Gy to the lungs by 2.9% (20.6 to 17.7%). This resulted
in a marginally increased (1) NTCPheart by 0.06% (0.5 to 0.6%) and decreased (2) NTCPlungs by
0.01% (0.04 to 0.03%), and (3) SCCPlin by 2.3% (18.2 to 15.9%). These differences are due to the
location of the edge of abutting beams, as the energies used for each comparison are identical.
Comparing Plan 4 (scanned, discrete energy beams, upper 18.4 MeV and lower 15.1 MeV)
with Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV) showed

83

no advantage to continuous energy. Rather, it showed the advantage of the field arrangement for
Plan 4, as Plan 5 increased (1) mean dose to the heart by 0.5 Gy (7.0 to 7.5 Gy) why the V20 Gy to
the lung remained constant at 16.5%. This resulted in increased (1) NTCPheart of 0.06% (0.3 to
0.4%), identical NTCPlungs values of 0.02%, and increased SCCPlin by 0.4% (13.7% to 14.1%).
Effect of Scanned, Continuous Beam Energies vs. Scattered, Discrete Beam Energies: This
comparison was overshadowed by the abutting border of Plan 5 being 0.25 cm inferior to that of
Plan 1. Plan 4 metrics were better than those of Plan 5, negating this comparison.
Summary: Results showed that scanned electron beams modestly reduced heart and lung
dose and their biologic effects. Continuous energy beams showed insignificant improvement over
discrete energy beams, because the discrete energies available were already optimal. More
significant was the location of the edge of abutting beams, indicating the need for optimizing its
location in future studies.
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Figure 3.28. Sagittal and axial images of CW7, Plans 1 and 2. CW7 (Patient Set 2) was planned
using scattered electron beams and discrete energy spacing for Plan 1 and scattered beams with
discrete energy spacing (lower field) and continuous energy spacing (upper field). Because the
discrete energy is the optimal energy for the upper field, Plans 1 and 2 are identical (a) Dose plan
in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s transverse plane;
(b) Dose plan in transverse plane passing through central heart region, demarcated by red line in
figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and
PTV is outlined in white. Key shows dose values.
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Figure 3.29. Sagittal and axial images of CW7, Plan 3. CW7 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
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Figure 3.30. Sagittal and axial images of CW7, Plan 4. CW7 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
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Figure 3.31. Sagittal and axial images of CW7, Plan 5. CW7 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.32. Comparison of cumulative DVH plots for CW7 (Patient Set 2) Plans. DVH plots for
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key
Table 3.8. Comparison of metrics for CW7 (Patient Set 2) Plans. Dose metrics are shown for PTV,
heart, and lungs. NTCP and SCCP values are shown for heart and lungs.

PTV

Heart

Lungs

D97% (Gy)
V47.5 Gy (%)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)

Plan 1
46.9
96.4
69.6
54.2
3.2

Plan 2
46.9
96.4
69.6
54.2
3.2

Plan 3
46.4
96.3
68.4
54.1
3.2

Plan 4
46.0
96.2
68.4
54.0
3.2

Plan 5
45.6
95.6
68.3
54.0
3.3

V22.5 Gy (%)
V30 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)

11.6
4.8
1.9
46.9
9.6
9.0
0.5

11.6
4.8
1.9
46.9
9.6
9.0
0.5

12.8
5.7
1.8
46.3
9.7
9.4
0.6

8.0
2.6
0.7
44.3
7.0
8.3
0.3

9.2
3.3
0.8
44.3
7.5
8.7
0.4

V20 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)
SCCPlin (%)
SCCPlin-exp (%)

20.6
0.9
99.4
19.5
24.3
0.04
18.2
4.0

20.6
0.9
99.4
19.5
24.3
0.04
18.2
4.0

17.7
0.4
97.7
17.0
23.1
0.03
15.9
3.7

16.5
0.2
95.7
14.6
22.3
0.02
13.7
3.0

16.5
0.2
97.5
15.1
23.1
0.02
14.1
3.0
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3.2.2.4.

Results for Patient CW8

Treatment planning results for CW8 (Patient Set 2) include isodose plots for three
transverse planes and one sagittal-coronal oblique plane for Plans 1 to 5. All such results are shown
in Appendix B, and one sagittal-coronal oblique plane and one transverse plane for each plan are
shown in Figure 3.33 to Figure 3.37. DVHs for PTV, heart, and lungs for each of the five dose
plans were computed and plotted for comparison in Figure 3.38. Dose and biologic metrics
computed from these DVHs are compared in Table 3.9. These results likely have some dependence
on the location of the distal PTV surface, and the CW8 distance between the distal edge of the
PTV and the distal side of the chest wall (Δt) was 0.6 cm on central axis.
PTV Coverage: Dose plots (Figure 3.33 to Figure 3.37) show that the 90% isodose lines
closely cover the distal PTV surface, or in some locations the 80% isodose surface due to the
jagged nature of the PTV. Most evident at the lateral edges of the PTV, coverage could be
improved by increasing the lateral margin between the PTV and field edge or by a more realistic
PTV (smoother edges). The PTV DVHs are similar for all plans; V47.5 Gy values of Plans 3 and 5,
which have the field arrangement used for the continuous energy beams (see Figure 2.3) are
slightly greater than those of Plans 1, 2, and 4, which use a different field arrangement (see Figure
2.2). Although maximum doses are as large as approximately 60 Gy (108%), no significant volume
receives more than 58 Gy (105%).
Effect of Scanned vs. Scattered Beams: Comparing Plan 1 (scattered, discrete energy
beams, upper 16.2 MeV and lower 13.0 MeV) and Plan 4 (scanned, discrete energy beams, upper
14.5 MeV and lower 12.2 MeV) showed that the scanned electron beam reduced (1) mean dose to
the heart by 0.6 Gy (4.3 to 3.7 Gy) and (2) V20 Gy to the lungs by 2.9% (17.7 to 14.8%). This
resulted in reduced (1) NTCPheart by 0.06% (0.1 to 0.06%), (2) NTCPlungs by 0.01% (0.02 to
0.01%), and (3) SCCPlin by 2.3% (13.1 to 10.8%).
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Comparing Plan 3 (scattered, continuous energy beams, upper 15.6 MeV and lower 11.1
MeV) and Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV)
showed that the scanned electron beam reduced (1) mean dose to the heart by 0.9 Gy (3.9 to 3.0
Gy) and (2) V20 Gy to the lungs by 3.2% (16.4 to 13.1%). This resulted in reduced (1) NTCPheart by
0.06% (0.1 to 0.06%), (2) NTCPlungs by 0.01% (0.02 to 0.01%), and (3) SCCPlin by 2.5% (12.2 to
9.7%).
Effect of Continuous vs. Discrete Beam Energies: The same data above can be used to
evaluate the benefit of continuous versus discrete energy beams. Comparing Plan 2 (scattered,
continuous energy beams, upper 15.6 MeV and discrete energy lower 13.0 MeV beam) with Plan
1 (scattered, discrete energy beams, upper 16.2 MeV and lower 13.0 MeV), there is insignificant
differences in PTV and heart metrics, as the only difference in plans was a 0.6 MeV lower energy
in the upper field. There were small changes in the lung metrics as Plan 2 showed reduced V20 Gy
to the lungs by 0.3% (17.7 to 17.4%) and (2) SCCPlin by 0.3% (13.1 to 12.9%).
Comparing Plan 2 (scattered, continuous energy beams, upper 15.6 MeV and discrete
energy lower 13.0 MeV beam) with Plan 3 (scattered, continuous energy beams, upper 15.6 MeV
and lower 13.0 MeV), differing only by the inferior border of the upper field being 0.75 cm
inferior, showed reduced (1) mean dose to the heart by 0.3 Gy (4.2 to 3.9 Gy) and (2) V20Gy to the
lungs by 1.0% (17.4 to 16.4%). This resulted in reduced (1) NTCPheart by 0.00% (0.1 to 0.1%), (2)
NTCPlungs by 0.00% (0.02 to 0.02%), and (3) SCCPlin by 0.7% (12.9 to 12.2%).
Comparing Plan 4 (scanned, discrete energy beams, upper 14.5 MeV and lower 12.2 MeV)
with Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV) showed
decreased (1) mean dose to the heart by 0.6 Gy (3.7 to 3.0 Gy) and (2) V20Gy to the lung by 1.6%
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(14.8 to 13.1%). This resulted in identical NTCPheart values of 0.06% and NTCPlungs vales of
0.01%, and decreased SCCPlin by 1.2% (10.8% to 9.7%).
Effect of Scanned, Continuous Beam Energies vs. Scattered, Discrete Beam Energies:
Even though the abutting border of the upper and lower fields differed, there was still benefit.
Comparing Plan 5 (scanned, continuous energy beams, upper 14.5 MeV and lower 10.5 MeV)
with Plan 1 (scattered, discrete energy beams, upper 16.2 MeV and lower 13.0 MeV) showed that
scanned, continuous energy beams reduced (1) mean dose to the heart by 1.3 Gy (4.3 to 3.0 Gy)
and (2) V20Gy to the lung by 4.6% (17.7 to 13.1%). This resulted in reduced (1) NTCPheart by 0.0%
(0.1 to 0.1%), (2) NTCPlungs by 0.0% (0.0 to 0.0%), and (3) SCCPlin by 3.4% (13.1% to 9.7%).
Summary: Results showed that scanned electron beams modestly reduced heart and lung
dose and their biologic effect. NTCP changes were not likely significant because of their already
low value for scattered beams. Continuous energy beams showed insignificant improvement over
discrete energy beams, because the discrete energies available were already near optimal. More
significant was the location of the edge of abutting beams, indicating the need for optimizing its
location in future studies.
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Figure 3.33. Sagittal and axial images of CW8, Plan 1. CW8 (Patient Set 2) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
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Figure 3.34. Sagittal and axial images of CW8, Plan 2. CW8 (Patient Set 2) was planned using
scattered electron beams, discrete energy spacing (lower field), and continuous energy spacing
(upper field). (a) Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in
figure (b)’s transverse plane; (b) Dose plan in transverse plane passing through central heart region,
demarcated by red line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus
is shaded light blue, and PTV is outlined in white. Key shows dose values.
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Figure 3.35. Sagittal and axial images of CW8, Plan 3. CW8 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
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Figure 3.36. Sagittal and axial images of CW8, Plan 4. CW8 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
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Figure 3.37. Sagittal and axial images of CW8, Plan 5. CW8 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
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Figure 3.38. Comparison of cumulative DVH plots for CW8 (Patient Set 2) Plans. DVH plots for
PTV, heart, and lung are compared for Plans 1, 2, 3, 4, and 5, as indicated in key
Table 3.9. Comparison of metrics for CW8 (Patient Set 2) Plans. Dose metrics are shown for PTV,
heart, and lungs. NTCP and SCCP values are shown for heart and lungs.
Plan 1 Plan 2 Plan 3 Plan 4 Plan 5
44.7
44.7
43.9
43.9
42.9
D97% (Gy)
92.5
92.5
93.7
91.6
91.5
V47.5 Gy (%)
58.4
58.4
60.0
58.4
59.1
PTV
Max dose (Gy)
52.2
52.2
52.5
52.1
52.2
Mean dose (Gy)
3.1
3.0
3.1
3.2
3.3
Std Dev (Gy)

Heart

Lungs

V22.5 Gy (%)
V30 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)

3.4
0.7
0.5
44.1
4.3
6.3
0.1

3.4
0.7
0.5
44.1
4.2
6.3
0.1

3.3
0.8
0.0
44.7
3.9
6.2
0.1

2.0
0.3
0.0
43.0
3.7
5.2
0.1

1.8
0.3
0.0
43.4
3.0
5.1
0.1

V20 Gy (%)
Min dose (Gy)
Max dose (Gy)
Mean dose (Gy)
Std Dev (Gy)
NTCP (%)
SCCPLin (%)
SCCPLin-Exp (%)

17.7
0.0
48.0
7.8
12.1
0.0
13.1
2.5

17.4
0.0
46.7
7.7
12.0
0.0
12.9
2.4

16.4
0.0
48.7
7.2
11.9
0.0
12.2
2.3

14.8
0.0
45.7
6.5
11.1
0.0
10.8
2.1

13.1
0.0
48.0
5.8
10.5
0.0
9.7
1.9
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Chapter 4. Discussion of Results
The purpose of this study was to determine the potential impact of availability of discrete
versus continuous beam energies and of beams flattened using scanned beam technology versus
dual scattering foils on the treatment of post-mastectomy breast cancer patients. The quality of
post-mastectomy radiotherapy treatment plans was evaluated by examining PTV coverage (chest
wall, excluding supraclavicular field), heart dose, and lung dose for left sided postmastectomy
patients. Both dose and biologic metrics were calculated for comparison of multiple plans for each
patient. In addition to the treatment modality dependences, the results of this study also showed
some dependence on beam energy, i.e. R90, (related to maximum thickness of PTV), distance of
tissue between distal PTV surface and distal chest wall surface (onset of lungs or heart), and
number of electron fields used to treat PTV (one versus two, the upper field of the latter having a
feathered edge). Below the impact of electron beam technology as well as patient and beam
parameters on dose and biologic metrics are discussed.
4.1. Impact on Heart Dose
For all IM-BECT treatment plans, dose to the heart was low due to using electron beams
with conformal bolus, as previously reported.21 For the seven patients studied, the maximum values
for V22.5Gy. V30Gy, and Dmean were 12.7%, 6.4%, and 9.6 Gy for Plan 1, which is the only plan
currently deliverable using clinically available technology (scattered, discrete energy beams).
These plans produced a maximum value for NTCP of 0.9%.
Effects of using scattered versus scanned beams were best assessed by comparing Plan 1
with Plan 4 and Plan 3 with Plan 5 for Patient Set 1, because they required only a single beam;
however, comparisons for Patient Set 2 were also meaningful, even though Plan 5 did not have the
optimal location of the abutment edge for the lower and upper fields. Plots of V22.5Gy. V30Gy,

99

and Dmean (scattered beam value less scanned beam value) versus R90 showed the general trend
that these metrics increased as R90 increased (see Figure 4.1). As expected, scanned beams showed
the greatest effect (benefit) at the higher energies (Rp  5 cm). For the seven patients studied,
maximum V22.5Gy. V30Gy, and Dmean values for Plan 4, which could be deliverable by scanned,
discrete energy beams, were reduced to 9.5%, 4.2%, and 7.0 Gy.

Figure 4.1. Reduction in heart dose metrics (scattered beam value less scanned beam value) versus
the average R90 of discrete and continuous energy beams overlying heart. The values shown are
the average of the differences in dose metrics between Plan 1 and Plan 4 and between Plan 3 and
Plan 5 (scattered beam value less scanned beam value). These plots illustrate the effect different
R90 values have on heart metrics. The general trend is that between scattered and scanned beams,
as the R90 increases, so do ΔV22.5Gy. ΔV30Gy, and ΔDmean. The CW patient number is indicated
inside the circles for Patient Set 1 (1,3,6) and squares for Patient Set 2 (2,4,7,8).
Effects of using continuous versus discrete energy beams were best assessed by comparing
Plan 1 with Plan 3 and Plan 4 with Plan 5 for Patient Set 1. Comparisons for Patient Set 2 were
not particularly informative because the location of the edge of abutting the upper and lower fields
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was not optimized. Plots of V22.5Gy. V30Gy, and Dmean (discrete energy beam value less
continuous energy beam value) versus R90 suggested the general trend that these metrics increased
as R90 increased (see Figure 4.2). Although only data for three patients, all showed improvement
with that for the highest energy beam (R90 = 6 cm) being the greatest; for Patient 1 V22.5Gy, V30Gy,
and Dmean values were reduced by 5.6 %, 2.2%, and 1.9 Gy, respectively. Appreciate that this effect
could be negligible if the discrete energy selected were the optimal energy; however, in some cases
both effects (large R90 and suboptimal energy) can be considerable.

Figure 4.2. Reduction in heart dose metrics (discrete energy beam value less continuous energy
beam value) versus the average R90 of discrete and continuous energy beams overlying heart. The
values shown are the average of the differences in dose metrics between Plan 1 and Plan 3 and
between Plan 4 and Plan 5 (discrete beam value less continuous beam value) for patients in Patient
Set 1. These plots illustrate the effect different R90 values have on heart metrics. The general trend
is that between discrete and continuous beams as the R90 increases, so do ΔV22.5Gy. ΔV30Gy, and
ΔDmean. The CW patient number (1,3,6) is indicated inside the circles.
Combining these effects, scanned, continuous energy beams can provide treatment plans
significantly superior to scattered, discrete energy beams. This is best illustrated by CW1, whose
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metrics for Plan 1 versus Plan 5 were reduced, V22.5Gy from 10.4% to 2.2%, V30Gy from 3.1% to
0.1%, Dmean from 8.3 Gy to 4.3 Gy, and NTCP from 0.4% to 0.1%.
Dose to the heart also depended on (1) the thickness of tissue (t) between the distal edge
of the PTV and the heart and (2) the energy (hence R90) required for PTV coverage. The former is
illustrated by comparing V22.5Gy. V30Gy, and Dmean versus t for Plan 1 (scattered, discrete energy
beams) for each of the seven patients planned in this study (see Figure 4.3), which showed the
trend that the smaller the value of t, the greater the heart dose. The latter is confirmed by
comparing V22.5Gy. V30Gy, and Dmean versus R90 for Plan 1 (scattered, discrete energy beams) for
each of the seven patients planned in this study ( see Figure 4.4), which showed the trend that the
greater the energy (hence R90), the greater the heart dose. Therefore, patient plans with the smaller
t and the greater R90 are those that possibly could benefit most from availability of scanned and/or
continuous energy beams.

Figure 4.3. Effect of Δt on heart metrics. These plots illustrate the effect of Δt values on heart
metrics for Plan 1. The general trend is that as Δt increases, V22.5Gy. V30Gy, and Dmean decrease. The
CW patient number is indicated inside the circles for Patient Set 1 (1,3,6) and squares for Patient
Set 2 (2,4,7,8).
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Figure 4.4. Effect of R90 on heart metrics. These plots illustrate the effect of R90 values on heart
metrics for Plan 1. The general trend is that as R90 increases, so do V22.5Gy. V30Gy, and Dmean. The
patient number is indicated inside the circles for Patient Set 1 (1,3,6) and squares for Patient Set 2
(2,4,7,8).
4.2. Impact on Lung Dose
For all IM-BECT treatment plans, dose to the lung was low due to using electron beams
with conformal bolus, as previously reported.21 For the seven patients studied, V20Gy values ranged
from 11.8% to 20.6% for Plan 1, the only plan deliverable using current scattered, discrete energy
beams. These doses are acceptably low, with NTCP values ranging from 0.01% to 1.4%. However,
SCCPlin values, which ranged from 10.9% to 18.6%, might be of greater clinical significance.
Effects of using scattered versus scanned beams were best assessed by comparing Plan 1
with Plan 4 and Plan 3 with Plan 5 for Patient Set 1, because they required only a single beam;
however, comparisons for Patient Set 2 were also meaningful, even though Plan 5 did not have the
ideal location of the abutment edge for the lower and upper fields. Plots of V20Gy and SCCPlin
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(scattered beam value less scanned beam value) versus R90 showed the general trend that these
differences increased as R90 increased (see Figure 4.5). In other words, as expected, scanned beams
showed greater benefit at the higher energies (Rp  5 cm). For the seven patients studied, V20Gy
values were reduced to range from 9.2% to 17.8% and SCCPlin values were reduced to range from
8.1% to 13.7% for Plan 4, which could be deliverable by scanned, discrete energy beams.

Figure 4.5. Reduction in lung dose metrics (scattered beam value less scanned beam value) versus
the average R90 of discrete and continuous energy beams overlying lung. The values shown are the
average of the differences in dose metrics between Plan 1 and Plan 4 and between Plan 3 and Plan
5 (scattered beam value less scanned beam value). These plots illustrate the effect different R90
values have on lung metrics. The general trend is that between scattered and scanned beams, as
R90 increases, so do ΔV20Gy and ΔSCCPlin. The CW patient number is indicated inside the circles
for Patient Set 1 (1,3,6) and squares for Patient Set 2 (2,4,7,8).
Effects of using continuous versus discrete energy beams were best assessed by comparing
Plan 1 with Plan 3 and Plan 4 with Plan 5 for Patient Set 1. Comparisons for Patient Set 2 were
not particularly informative because the location of the edge of abutting the upper and lower fields
abutment was not optimized. Plots of V20Gy and SCCPlin (discrete energy beam value less
continuous energy beam value) versus R90 suggested the general trend that these differences
increased as R90 increased (see Figure 4.6). Although only data for three patients, all showed
improvement with that for the highest energy beam (R90 = 6 cm) being the greatest, for Patient 1,
reducing V20Gy and SCCPlin by as much as 3.1 % and 2.6%, respectively. Appreciate that this effect
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could be negligible if the discrete energy selected is the optimal energy; however, in some cases
both effects (large R90 and suboptimal energy) can be considerable.
Combining these effects, scanned, continuous energy beams can provide treatment plans
significantly superior to scattered, discrete energy beams. This is best illustrated by CW1, whose
metrics for Plan 1 versus Plan 5 were reduced significantly, V20Gy from 17.2% to 10.7% and
SCCPlin from 14.4% to 8.7%.

Figure 4.6. Reduction in lung dose metrics (discrete energy beam value less continuous energy
beam value) versus the average R90 of discrete and continuous energy beams overlying lung. The
values shown are the average of the differences in dose metrics between Plan 1 and Plan 3 and
between Plan 4 and Plan 5 (discrete beam value less continuous beam value) for patients in Patient
Set 1. These plots illustrate the effect different R90 values have on lung metrics. The general trend
is that between discrete and continuous beams as the R90 increases, so do ΔV30Gy and ΔSCCPlin.
The CW patient number (1,3,6) is indicated inside the circles.
4.3. Location of Abutting Edge
Although the chest wall field can be treated with a single energy field using IM-BECT, it
is often beneficial to treat a superior (upper) field using a higher electron energy and the inferior
(lower) field using a lower electron energy, so as to reduce heart dose, as discussed above. This
raises the questions of (1) where to put the abutting edge and (2) how to match the penumbras.
The latter, described in this work, was achieved by using a common virtual source and feathering
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the sharper, higher energy beam penumbra to closely match that of the broader, lower energy beam
penumbra.
Regarding the former, placing the edge too superior can result in having to increase the
energy of the inferior field to the detriment of increasing heart dose. Placing the edge too inferior
can result in greater dose than necessary to parts of the lung, as well as additional heart dose from
the bulging of the high energy penumbra of the upper field into the heart. Such was the case in the
present study by placing the edge 1 cm superior to the superior extent of the heart. This is illustrated
by comparing the heart doses for Plan 2 and Plan 3 in Patient Set 2. For (CW2, CW4, CW7, and
CW8), the V22.5Gy heart dose mostly increased from (3.1, 0.4, 11.6, and 3.4 Gy) to (8.4, 0.6, 12.8,
and 3.3 Gy), and the Dmean heart dose changed from (4.6, 3.8, 9.7, and 4.2 Gy) to (8.1, 3.6, 9.7, and
3.9 Gy); however, the NTCP decreased or remained the same from (0.9, 0.01, 0.5, and 0.1%) to
(0.3, 0.01, 0.6, and 0.1%). The increased V22.5Gy was indicative of the encroachment of the higher
energy dose, and the reduced NTCP was likely due to the differences in PTV volumes being
treated.
4.4. Comparison of IM-BECT with VMAT Plans
The best IM-BECT plans can be compared with VMAT plans used to treat these patients
at MBPCC, which have been previously reported.20 For Patient Set 1, Plan 5 (scanned, continuous
energy beams) gives the best results and will be used for comparison. For Patient Set 2, Plan 4
(scanned, discrete energy beams) will be used, as the optimal location of the edge of the abutting
electron fields was not used in Plan 5. Plan comparisons for Patient Set 1 should be reasonable, as
there was no supraclavicular field. However, comparison of plans in Patient Set 2 is somewhat
presumptuous, as the current study did not include planning x-ray beams (possibly IMXT) for the
supraclavicular field. However, assuming that supraclavicular fields contribute insignificantly to
heart and lung dose, comparison of those metrics should be reasonable.
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Selected metrics for the heart and lung are compared in Table 4.1 and Table 4.2,
respectively. The results for Patient Sets 1 and 2 are similar; therefore, it is reasonable to report
and discuss the results together, which are also computed (averages and standard deviations).
Almost all data show that the standard deviations of VMAT plan metrics are small relative to those
of the IM-BECT plans. This is possibly due to electron beam plans depending more on beam
energy and t. Regardless, the increased spread means that some IM-BECT plans will be better or
worse than the average, which means the degree of benefit of IM-BECT requires a plan comparison
for the specific patient.
Table 4.1. Comparison of heart dose and biologic metrics for IM-BECT and VMAT Plans from
Doiron (2018).41 Plan 4 utilizes scanned, discrete energy beams for IM-BECT, and Plan 5 utilizes
scanned, continuous energy beams for IM-BECT.
Modality-Plan
V22.5Gy (%) Dmean (Gy) NTCP (%)
Patient Set 1
CW1

VMAT
IM-BECT Plan 5
VMAT
IM-BECT Plan 5
VMAT
IM-BECT Plan 5
VMAT
IM-BECT Plan 5

9.7
2.3
5.5
1.5
11.5
8.2
8.9 (3.1)
4.0 (3.7)

9.0
4.3
7.0
3.7
10.9
5.8
9.0 (2.0)
4.6 (1.1)

0.7
0.05
0.3
0.03
1.6
0.40
0.87 (0.54)
0.16 (0.21)

VMAT
IM-BECT Plan 4
VMAT
IM-BECT Plan 4
VMAT
IM-BECT Plan 4
VMAT
IM-BECT Plan 4
VMAT
IM-BECT Plan 4

11.0
1.7
9.2
0.1
8.7
8.0
10.1
2.0
9.8 (1.0)
3.0 (3.5)

10.2
3.9
9.2
2.4
9.4
7.0
9.3
3.7
9.5 (0.5)
4.3 (2.0)

1.0
0.40
0.3
0.00
0.5
0.31
0.6
0.06
0.6 (0.3)
0.2 (0.2)

Patient Sets 1 & 2
Mean (Std Dev)
VMAT
9.4 (2.0)
IM-BECT Plan 4/5 3.4 (3.3)

9.3 (1.2)
4.4 (1.5)

1.0 (0.7)
0.2 (0.2)

CW3
CW6
Mean (Std Dev)
Patient Set 2
CW2
CW4
CW7
CW8
Mean (Std Dev)
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For the heart, on average, V22.5Gy dose is reduced from 9.8% for VMAT to 3.0% for IMBECT and Dmean is reduced from 9.3 Gy to 4.4 Gy. Although both are significant, NTCP is only
reduced from 1.0% to 0.2%, as both are clinically low. So, although the dose reductions are
significant, the NTCP models show minor clinical benefit.
For the lungs, average V20Gy doses are similar, being 13.1% for VMAT and 13.0% for IMBECT; however, values are 14.1% and 9.2% for CW4, demonstrating patient variability. Average
Dmean doses are reduced from 8.8 Gy to 7.1 Gy. Average NTCP is reduced from 2.8% to 0.2% and
SCCPlin is reduced from 15.1% to 10.2%. These differences might further improve (increase) by
optimizing the location of the abutting edge for IM-BECT Plan 5.
Table 4.2. Comparison of lungs dose and biologic metrics for IM-BECT and VMAT Plans. Plan
4 utilizes scanned, discrete energy beams for IM-BECT, and Plan 5 utilizes scanned, continuous
energy beams for IM-BECT.
Modality-Plan
V20Gy (%)
Dmean (Gy) NTCP (%) SCCPlin
Patient Set 1
CW1
VMAT
13.4
8.7
2.7
14.9
IM-BECT Plan 5
10.7
5.2
0.01
8.7
CW3
VMAT
13.1
8.8
2.8
15.1
IM-BECT Plan 5
12.5
5.6
0.01
9.4
CW6
VMAT
14.3
9.9
3.4
16.8
IM-BECT Plan 5
16.8
7.6
0.02
12.8
Mean (Std Dev)
VMAT
13.6 (0.6)
9.1 (0.7)
3.0 (0.4)
15.6 (1.0)
IM-BECT Plan 5
13.3 (3.1)
6.1 (1.3)
0.01 (0.01) 10.3 (2.2)
Patient Set 2
CW2
VMAT
13.5
8.5
2.7
14.7
IM-BECT Plan 4
10.5
5.3
1.0
8.9
CW4
VMAT
14.1
9.2
3.0
15.7
IM-BECT Plan 4
9.2
4.8
0.01
8.1
CW7
VMAT
11.0
8.6
2.7
14.6
IM-BECT Plan 4
16.5
14.6
0.02
14.1
CW8
VMAT
12.4
8.0
2.4
13.8
IM-BECT Plan 4
14.8
6.5
0.01
9.7
Mean (Std Dev)
VMAT
12.8 (1.4)
8.6 (0.5)
2.7 (0.3)
14.7 (0.8)
IM-BECT Plan 4
12.8 (3.5)
7.8 (4.6)
0.3 (0.5)
10.2 (2.7)
Patient Sets 1 & 2
Mean (Std Dev)
VMAT
13.1 (1.1)
8.8 (0.6)
2.8 (0.3)
15.1 (0.9)
IM-BECT Plan 4/5 13.0 (3.1)
7.1 (3.4)
0.2 (0.4)
10.2 (2.3)
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Chapter 5. Summary of Results, Conclusion, and Future Works
5.1. Summary of Results
5.1.1. IM-BECT Plans Using Different Electron Beam Machines
IM-BECT treatment plans were generated for seven left-sided postmastectomy radiotherapy
patients previously treated at MBPCC using VMAT. The patients were divided into two sets:
Patient Set 1, which was comprised of three patients (CW1,CW3,CW6) and required a single
electron field to treat the chest wall PTV, and Patient Set 2, which was comprised of four patients
(CW2,CW4, CW7, CW8) and required two electron fields of differing energies to treat the chest
wall PTV. For this study, only the chest wall PTV was studied, and the supraclavicular field, which
requires photon beams to treat, was excluded. For patients in Patient Set 2, the inferior edge of the
upper field was feathered to match the penumbra of the lower field. Thus, three beams were used
to cover the chest wall PTV for these patients.
Four IM-BECT treatment plans were made for each patient in Patient Set 1, and five IM-BECT
plans were made for each patient in Patient Set 2. These plans spanned the spectrum from currently
available electron radiotherapy technology, scattered, discrete energy beams, to hypothetical
scanned, continuous energy beams. The treatment plans also included scattered, continuous energy
beams and scanned, discrete energy beams. To determine the effects of using scattered vs. scanned
beams, as well as the effects of using discrete vs. continuous energy spacing, the planar isodose
plots, DVHs, and dose and biologic metrics were extracted from the dose distribution for each of
32 plans.
5.1.2. Impact of Machine Technology on Heart Dose
Compared to other PMRT techniques, IM-BECT treatment plans typically have low heart
dose,21 which is due to the use of conformal electron bolus and dose distributions of electron
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beams. For the seven patients studied, the V22.5Gy, V30Gy, and Dmean maximum values were 12.7%,
6.4%, and 9.6 Gy for Plan 1, which uses currently deliverable scattered, discrete energy beams.
These doses are low, having maximum NTCP of 0.9%.
When comparing scattered and scanned beam metrics, V22.5Gy, V30Gy, and Dmean
(scattered beam value less scanned beam value) versus R90 showed these metrics increased as R90
increased, i.e. scanned beams showed the greatest effect (benefit) at the higher energies (Rp  5
cm). For the seven patients studied, maximum V22.5Gy, V30Gy, and Dmean were reduced to 9.5%,
4.2%, and 7.0 Gy for Plan 4, which could be deliverable by scanned, discrete energy beams.
When comparing discrete and continuous energy beams, V22.5Gy, V30Gy, and Dmean
(discrete energy beam value less continuous energy beam value) versus R90 suggested that these
metrics increased as R90 increased. Although only data for three patients (Patient Set 1) was used,
all showed improvement, that for the highest energy beam (R90 = 6 cm) being the greatest with
V22.5Gy, V30Gy, and Dmean values being reduced by as much as 4.6 %, 2.2%, and 1.9 Gy, respectively.
Of course, this effect could be negligible if the discrete energy selected was equal or near the
optimal energy.
In some patient cases, the effects of using both scanned and continuous energy beams were
observed. This is clearer for patients in Patient Set 1 because there were no abutment issues. If we
compare Plan 5 and Plan 1 metrics for CW1, there were reductions in V22.5Gy from 10.4% to 2.2%,
V30Gy from 3.1% to 0.1%, Dmean from 8.3 Gy to 4.3 Gy, and NTCP from 0.4% to 0.1%.
For all patients, the beam energy required for the lower field (based on maximum PTV
thickness) and the thickness of tissue between the distal edge of the PTV and the heart (t) affected
heart dose. Looking at Plan 1 for all patients shows that heart dose (1) decreased as the thickness
of tissue (t) between the distal PTV edge and the heart increased and (2) increased as the R90
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(hence energy) required for PTV coverage increased. Therefore, patient plans with the smaller t
and greater R90 are those that possibly could benefit most from availability of scanned and/or
continuous energy beams with regards to heart dose.
5.1.3. Impact of Machine Technology on Lung Dose
For all IM-BECT treatment plans, dose to the lung was low due to using electron beams with
conformal bolus, as previously reported.41 For the seven patients studied, V20Gy values ranged from
11.8% to 20.6% for Plan 1, the only plan deliverable using current scattered, discrete energy
beams. These doses are acceptably low, having NTCP values ranging from 0.01% to1.4%.
However, reducing SCCPlin values, which ranged from 10.9% to 18.6%, could be of concern.
Effects of using scattered versus scanned beams were best assessed by comparing Plan 1 with
Plan 4 and Plan 3 with Plan 5 for Patient Set 1, because they required only a single beam; however,
comparisons for Patient Set 2 were also meaningful, even though Plans 3 and 5 did not have the
optimal location of the abutment edge for the lower and upper fields. Plots of V20Gy and SCCPlin
(scattered beam value less scanned beam value) versus R90 showed the general trend that lung
sparing benefitted from scanned beams and that the benefit increased as R90 increased. For the
seven patients studied, V20Gy values ranged from 9.2% to 17.8% and SCCPlin values ranged from
8.1% to 13.7% for Plan 4 (scanned, discrete energy beams). Improving location of the abutting
edge for the upper and lower electron fields should further increase the benefit for Patient Set 2.
Effects of using continuous versus discrete energy beams were assessed by comparing Plan 1
with Plan 3 and Plan 4 with Plan 5 for Patient Set 1. Plots of V20Gy and SCCPlin (discrete beam
energy value less continuous beam energy value) versus R90 suggested the general trend that lung
sparing benefitted from continuous beam energy and that the benefit increased as R90 increased.
Although only data for three patients, all showed improvement. The greatest, Patient CW1 (R90 =
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6 cm), showed V20Gy and SCCPlin reduced by 3.1 % and 2.6%, respectively. As for the heart, this
effect could be negligible if the discrete energy selected was the optimal energy.
In some cases, the effects of using both scanned and continuous energy beams are significant.
This is clearest for patients in Patient Set 1 because there are no abutment issues. Comparing Plan
5 metrics with Plan 1 metrics for CW1 shows that lung metrics are significantly reduced, V20Gy
from 17.2% to 10.7% and SCCPlin from 14.4% to 8.7%.
5.1.4. Impact of Location of Abutting Edge
For patients in Patient Set 2, the location of the abutting edge had a significant impact on the
dose distribution and the heart and lung metrics. Placing the edge too superior can result in having
to increase the energy of the inferior field to the detriment of increasing heart dose. Placing the
edge too inferior can result in greater dose than necessary to parts of the lung, as well as additional
heart dose from the bulging of the high energy penumbra of the upper field into the heart. Such
was the case in the present study by placing the edge 1 cm superior to the superior extent of the
heart. This was illustrated by comparing the heart dose for Plan 2 and Plan 3 in Patient Set 2. For
(CW2, CW4, CW7, and CW8), V22.5Gy heart dose generally increased or changed little, from (3.1,
0.4, 11.6, and 3.4 Gy) to (8.4, 0.6, 12.8, and 3.3 Gy), and Dmean heart dose generally increased or
changed little, from (4.6, 3.8, 9.7, and 4.2 Gy) to (8.1, 3.6, 9.7, and 3.9 Gy); however, NTCP
decreased or changed little, from (0.9, 0.01, 0.5, and 0.1%) to (0.3, 0.01, 0.6, and 0.1%). For CW2
the increased heart V22.5Gy was most indicative of the encroachment from the higher energy upper
field.
5.2. Response to Hypothesis
Hypothesis: For seven post-mastectomy radiotherapy left-side chest wall patients
previously treated with volumetric modulated arc therapy (VMAT), treatment plans using intensity
modulated bolus electron conformal therapy (IM-BECT) with a scanned electron beam and/or the
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capability of continuous energy spacing can be superior (increased sparing of heart and lung and
reduced chance of secondary cancer) to plans made using IM-BECT with a passively scattered
electron beam and discrete Elekta energy spacing.
True, although a small sample of patients (seven), this study showed that IM-BECT treatment
plans using scanned and/or continuous energy beams provided plans superior to plans using current
scattered, discrete energy beams for some, but not all, patient plans.

5.3. Potential Clinical Impact
5.3.1. Impact of Scanned, Continuous Energy Beams
Availability of scanned, continuous energy beams would provide treatment plans superior to
those currently available, which use scattered, discrete energy beams. However, there are several
caveats to consider and possibly further study.
Previous studies have shown that IM-BECT offers increased dose sparing to the heart as
opposed to other PMRT techniques.21 For some patients, that benefit can be further increased using
scanned and/or continuous energy beams, as illustrated by this study. Better understanding of this
benefit requires additional studies. Also, the NTCP for the scattered, discrete energy beam plan is
quite low, perhaps minimizing the impact of improved plans.
Shown in this study, lung dose can be reduced using scanned, continuous energy beams;
however, the impact on NTCP is small, but perhaps of value for some patients. SCCPlin is
significantly less using scanned, continuous energy beams, and it could likely be further improved
by optimizing the abutting edge.
The benefit of scanned, continuous energy beams depends on the patient geometry, specifically
the depth of the PTV (hence R90) and the distance between the PTV distal surface and the proximal
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surface of the heart (Δt). The benefits of using these proposed modalities varied between the
different patients in this study. Further studies could better identify patient indications for using
scanned, continuous energy electron beams.
The current study was suboptimal due to its suboptimal methods of selecting the abutting edge
of the upper and lower fields. Hence, benefit of scanned and/or continuous energy beams should
improve with an optimized edge.
It appears that the benefit of scanned beam technology might be more significant than
continuous beam technology. This is in part due to the discrete energy beam possibly being the
optimal energy. However, the scanned beam always produces a sharper dose falloff, improving
the dose distribution. Also, the improvement in dose falloff (R90-10) is always more for scanned
versus scattered beam than using a slightly lower beam energy available with continuous energy
beams.
5.3.2. Comparison of IM-BECT and VMAT Treatment Plans
The best possible IM-BECT plans, Plan 5 for Patient Set 1 and Plan 4 for Patient Set 2,
were compared with patient VMAT plans from our clinic.20 Because the IM-BECT plans excluded
the supraclavicular PTV, only lung and heart dose were compared.
For heart dose, the average V22.5Gy was reduced from 9.8% for VMAT to 3.0% for IMBECT, and average Dmean was reduced from 9.3 Gy to 4.4 Gy. Although such reductions were
significant, NTCP models showed only minor average reduction from 1.0% to 0.2%, both
clinically low.
For lung dose, the average V20Gy doses were similar, 13.1% for VMAT and 13.0% for IMBECT; however, values were 14.1% and 9.2%, respectively for CW4, demonstrating patient
variability for benefits of IM-BECT. Average Da was reduced from 8.8 Gy to 7.1 Gy; however,
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average NTCP was reduced from 2.8% to 0.2%, and average SCCPlin was reduced from 15.1% to
10.2%. SCCPlin was reduced from 15.7% to 8.1% for CW4, demonstrating the potential benefit
for a single patient.
These results show that for some patients, IM-BECT can provide plans that are
significantly superior to VMAT.
5.4. Recommendations for Future Investigation
5.4.1. Revised Simple Planning Method
In future studies, it is recommended that only four plans be generated for each patient in
Patient Set 2, as was the done in Patient Set 1. The four plans should use (1) scattered, discrete
energy beams, (2) scattered, continuous energy beams, (3) scanned, discrete energy beams, and
(4) scanned, continuous energy beams. Each plan should use the following steps:
1. Location of Abutting Edge: Select the lowest continuous energy (R90) possible for
a field covering only the heart PTV. Then, move the superior edge of the lower
field superiorly as much as possible, while treating the chest wall with the 90%
dose surface. That field edge specifies the abutting edge of the lower and upper
fields for Plans 1 – 4.
2. Lower and Upper Field Beam Energies: Select the lowest available energies
available (discrete or continuous depending) for the lower and upper fields for
which the 90% dose surface contains the PTV.
3. Edge Feathering: Use the same procedure for feathering of the upper field edge as
specified in the present methods.
Alternatively, the lowest energy (continuous or discrete) possible for a field covering only
the heart PTV can be used. Then, the superior edge of the lower field can be moved superiorly as
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much as possible while treating the chest wall with the 90% dose surface. That field edge is used
only for that plan.
5.4.2. Revised Complex Planning Method
This method optimizes the location of the abutting edge. It is recommended that a fast
method be developed for finding the optimal location of the abutting edge between the upper,
greater energy field and the lower, lesser energy field. This is needed for those patients in Patient
Set 2, which required upper and lower fields of differing beam energy.
In the present study, in Plans 3 and 5, the edge was 1.0 cm superior to the superior aspect
of the heart. This allowed selection of the lowest available energy for the field overlying the heart;
however, it did not necessarily give the lowest heart dose, due to dose from the bulging edge of
the higher energy upper field reaching the heart. Also, because the energy had to be sufficiently
high to cover the superior aspect of the chest wall, where PTV depth can be deeper, it resulted in
a higher dose than needed over portions of the lung. Although bolus electron conformal therapy
places R90 at the distal PTV, a higher energy than necessary results in a greater R 90-10, giving
greater than necessary dose to lung. As the field edge is moved superiorly, the lung receives less
dose, as a greater portion of the lung is irradiated with the lower energy lower field. However, the
heart dose can increase if a slightly greater energy is required. Therefore, any optimization criteria
need to quantify the benefit of these competing effects of decreased lung dose at the expense of
increased heart dose.
5.4.3. Increasing Number of Patients for the Study
It is recommended that the number of patients in the study be increased approximately an
order of magnitude. Results showed that the amount of heart dose depended on the distance
between the distal PTV surface and the heart R90 of the energy required for the lower field.
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In addition, the benefit of continuous versus discrete energy beams, for both lung and heart
dose, depends on how close the ideal continuous energy is to the next greatest discrete energy
required. Also, the benefit of scanned versu41s scattered beams is greatest for higher energy beam
( 15 MeV). Therefore, for the right conditions, currently available scattered, discrete energy
beams might be very close to optimal. Also, for the right conditions, scanned and/or continuous
energy beams might significantly improve treatment than using currently available scattered,
discrete energy beams. Hence, a larger number of patients is required to determine the fraction that
might benefit and the amount they might benefit from either scattered, continuous energy; scanned,
discrete energy; or scanned, continuous energy beams.
5.4.4. Including the Supraclavicular Field in the Study
New IM-BECT patient plans should also include comparison with VMAT treatment plans.
To make that comparison complete, the supraclavicular PTV should be included with the electron
plan, treated either with VMAT or opposed IMXT as demonstrated by Doiron (2018). This should
demonstrate the benefit of IM-BECT over VMAT for currently available scattered, discrete energy
beams, as well as potential future beams using scattered, continuous energy beams; scanned,
discrete energy beams; or scanned, continuous energy beams.
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Appendix A.

Description of p.d Bolus Design Operators

Table A.1 Description of p.d Bolus Design Operators
Operators used to design the bolus for ECT using p.d are based on a subset of the operators of
Low et al. (1992) with some small changes. For more detail, refer to the p.d user manual.

Construction and Extension Operators
Creation Operator, Cp (𝑹𝒕 , 𝑰 )
Rt is a user specified therapeutic range (typically R90).
∆𝑰 is a user specified target inner margin, which is a distance, in the plane of the
isocenter, between the edge of the target volume and the solid angle within which the
initial bolus is designed.
This operator creates an initial bolus surface. With respect to the source, the proximal
patient skin surface defines the distal bolus surface. Cp only defines proximal bolus surface
for ray-lines intersecting the target volume less target inner margin (TVLM) by bolus
thickness 𝒃𝒊,𝒋 along each (i,j) ray-line, where 𝒃𝒊,𝒋 = (𝑹𝒕 − 𝒅𝒊,𝒋 )
where:
𝒅𝒊,𝒋 is the distance from the proximal patient surface to the distal target surface along the
(𝒊, 𝒋) ray-line;
Note: If 𝒃𝒊,𝒋 < 𝟎. 𝟐 𝒄𝒎, 𝒃𝒊,𝒋 = 𝟎. 𝟐 𝒄𝒎.
The bolus surface is extended laterally using the height extension operator below.

Height Extension Operator, Hh (𝑰 , 𝑶 )
∆𝑶 is a user specified block outer border margin, which is the distance, in the isocenter
plane, between the inner edge of the custom electron applicator (block) and the
unmilled region of the wax bolus (i.e. the block outer border).
This operator extends bolus height on (i,j) ray-lines within the TVLM to the block outer
border. The extended bolus heights 𝑯𝒊′ ,𝒋′ are defined separately for three zones (Low et al.
1992). In this work bolus heights in zone 1 were defined as the shorter of 𝒉𝒊,𝒋 or the
harmonic mean of (𝒉𝒊,𝒋 )𝒙 and (𝒉𝒊,𝒋 )𝒚 . Zones 2 and 3 are defined as per Low et al.
where:
𝒉𝒊,𝒋 is the nearest neighbor of 𝑯𝒊′ ,𝒋′ within the TVLM.
(𝒉𝒊,𝒋 )𝒙 is the nearest neighbor of 𝑯𝒊′ ,𝒋′ , where 𝒋 = 𝒋′.
(𝒉𝒊,𝒋 )𝒚 is the nearest neighbor of 𝑯𝒊′ ,𝒋′ , where 𝒊 = 𝒊′.

(table cont’d)
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Table A.1 Description of p.d Bolus Design Operators, cont.
Modification Operators
Isodose Shift Operator, I (%D, 𝑰 )
%D is a user definition of a distal percent dose surface (𝒅𝒊,𝒋 ) specified as percent given
%𝑫
dose. (Typically, %D = 90%)
Isodose Shift tries to match (𝒅𝒊,𝒋 ) to a distal target surface (𝒅𝒊,𝒋 )
by modifying
%𝑫

bolus thickness (𝒃𝒊,𝒋 )

𝒐𝒍𝒅

as (𝒃𝒊,𝒋 )

𝒏𝒆𝒘

𝒕𝒂𝒓𝒈𝒆𝒕

= (𝒃𝒊,𝒋 )

𝒐𝒍𝒅

+ (𝒅𝒊,𝒋 )

%𝑫

− (𝒅𝒊,𝒋 )

𝒕𝒂𝒓𝒈𝒆𝒕

.

Smoothing Operator, Gh (𝝁, 𝜼, 𝒑𝒔)
𝝁 is a user specified exponential smoothing weight coefficient.
𝜼 is a user specified smoothing region size factor.
a2 is a predefined to be 15mm.
𝟐
𝟐
∑𝜼𝒂[𝒉𝒊′ ,𝒋′ 𝒆−𝝁𝒓 ⁄(𝟐𝒂 ) ]
(𝒉𝒊,𝒋 )
(𝝁, 𝜼, 𝒑𝒔) =
𝟐
𝟐
𝒔𝒎𝒐𝒐𝒕𝒉
∑𝜼𝒂[𝒆−𝝁𝒓 ⁄(𝟐𝒂 ) ]
where:
(𝒉𝒊,𝒋 )
is the smoothed bolus height on each (𝒊, 𝒋) ray-line.
𝒔𝒎𝒐𝒐𝒕𝒉
a is bolus point spacing ps projected on each (𝒊, 𝒋) ray-line to the distal target surface.
𝒉𝒊′ ,𝒋′ is unsmooth bolus height along (𝒊′ , 𝒋′) ray-lines within the region 𝜼𝒂.
r is the distance from an (𝒊, 𝒋) ray-line to an (𝒊′ , 𝒋′) ray-line, where r ≤ 𝜼𝒂.
Specified Shift Operator, S (, 𝑶 )
 is a specified shift of the milled bolus surface.
This operator shifts the entire proximal bolus surface inside the block outer border toward
the beam source by , effectively changing the bolus thickness along each (i,j) ray-line to
𝒃𝒊,𝒋 = 𝒃𝒊,𝒋 + . A negative value of  shifts the entire proximal bolus surface inside the
block outer border away from the beam source, shifting isodose lines (IDL) deeper into the
patient.
Truncation Operator, T (𝑶 )
This operator only modifies the proximal bolus surface outside the block outer border
defined by 𝑶 by truncating bolus height 𝒉𝒊,𝒋 on each (i,j) ray to (𝒉𝒊,𝒋 )𝒎𝒂𝒙 .
where:
(𝒉𝒊,𝒋 )𝒎𝒂𝒙 is the maximum bolus surface height within the block outer border.
Modulate Intensity Operator, M (𝑰 , 𝒘𝒎𝒂𝒙 )
This operator modifies weights wi,j of each PBRA pencil beam intersecting the TVLM, i.e.
within 𝑰 , as (𝒘𝒊,𝒋 )
= (𝒘𝒊,𝒋 ) ∙ 𝒎𝒊𝒏[𝒘𝒎𝒂𝒙 , 𝟏𝟎𝟎%⁄𝒅𝒎𝒂𝒙(𝒊,𝒋) ]. Presently, the 1st
𝒏𝒆𝒘

𝒐𝒍𝒅

application of M in p.d uses (𝒘𝒊,𝒋 ) = (𝒘𝒊,𝒋 )
= 𝟏. 𝟎 .
𝒐𝒍𝒅
𝒊𝒏𝒊𝒕𝒊𝒂𝒍
where:
𝒅𝐦𝐚𝐱(𝒊,𝒋) is the maximum dose along each (i,j) ray-line.
𝒘𝒎𝒂𝒙 is the un-normalized maximum pencil beam weight (1.1 in this work).
Outside the TVLM, IM weights are extended according to Low et al.
The pencil beam weights are converted to a island block distribution for calculation as
described by Hilliard30
119

Appendix B.
B.1.

Treatment Planning Results

Patient Set 1 (CW1, CW3, CW6)

Figure B.1. Sagittal and axial images of CW1, Plan 1. CW1 (Patient Set 1) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.2. Sagittal and axial images of CW1, Plan 2. CW1 (Patient Set 1) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.3. Sagittal and axial images of CW1, Plan 4. CW1 (Patient Set 1) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.4. Sagittal and axial images of CW1, Plan 5. CW1 (Patient Set 1) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.5. Sagittal and axial images of CW3, Plan 1. CW3 (Patient Set 1) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.6. Sagittal and axial images of CW3, Plan 3. CW3 (Patient Set 1) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.7. Sagittal and axial images of CW3, Plan 4. CW3 (Patient Set 1) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.8. Sagittal and axial images of CW3, Plan 5. CW3 (Patient Set 1) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.9. Sagittal and axial images of CW6, Plan 1. CW6 (Patient Set 1) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.10. Sagittal and axial images of CW6, Plan 3. CW6 (Patient Set 1) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.11. Sagittal and axial images of CW6, Plan 4. CW6 (Patient Set 1) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Bolus is
shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.12. Sagittal and axial images of CW6, Plan 5. CW6 (Patient Set 1) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Bolus is shaded blue, and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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B.2.

Patient Set 2 (CW2, CW4, CW7, CW8)

Figure B.13. Sagittal and axial images of CW2, Plan 1. CW2 (Patient Set 2) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
(figure cont’d.)
144

145

Figure B.14. Sagittal and axial images of CW2, Plan 2. CW2 (Patient Set 2) was planned using
scattered electron beams and discrete (lower field)/continuous (upper field) energy spacing. (a)
Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s transverse
plane; (b) Dose plan in transverse plane passing through central heart region, demarcated by red
line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue,
and PTV is outlined in white. Key shows dose values.
(figure cont’d.)

146

147

Figure B.15. Sagittal and axial images of CW2, Plan 3. CW2 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.16. Sagittal and axial images of CW2, Plan 4. CW2 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
(figure cont’d.)

150

d

151

Figure B.17. Sagittal and axial images of CW2, Plan 5. CW2 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.18. Sagittal and axial images of CW4, Plan 1 and Plan 2. CW4 (Patient Set 2) was
planned using scattered electron beams and discrete energy spacing for Plan 1 and discrete (lower
field)/continuous (upper field) energy spacing for Plan 2. In this case, the optimal energy for the
upper field was discrete so the Plans 1 and 2 are identical. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.19. Sagittal and axial images of CW4, Plan 3. CW4 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.20. Sagittal and axial images of CW4, Plan 4. CW4 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
(figure cont’d.)
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Figure B.21. Sagittal and axial images of CW4, Plan 5. CW4 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.22. Sagittal and axial images of CW7, Plan 1 and Plan 2. CW7 (Patient Set 2) was
planned using scattered electron beams and discrete energy spacing for Plan 1 and discrete (lower
field)/continuous (upper field) energy spacing for Plan 2. In this case, the optimal energy for the
upper field was discrete so the Plans 1 and 2 are identical. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.23. Sagittal and axial images of CW7, Plan 3. CW7 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.24. Sagittal and axial images of CW7, Plan 4. CW7 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
(figure cont’d.)
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Figure B.25. Sagittal and axial images of CW7, Plan 5. CW7 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.26. Sagittal and axial images of CW8, Plan 1. CW8 (Patient Set 2) was planned using
scattered electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
(figure cont’d.)
170

171

Figure B.27. Sagittal and axial images of CW8, Plan 2. CW8 (Patient Set 2) was planned using
scattered electron beams and discrete (lower field)/continuous (upper field) energy spacing. (a)
Dose plan in the sagittal-coronal, oblique plane demarcated by the red line in figure (b)’s transverse
plane; (b) Dose plan in transverse plane passing through central heart region, demarcated by red
line in figure (a)’s oblique plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue,
and PTV is outlined in white. Key shows dose values.
(figure cont’d.)
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Figure B.28. Sagittal and axial images of CW8, Plan 3. CW8 (Patient Set 2) was planned using
scattered electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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Figure B.29. Sagittal and axial images of CW8, Plan 4. CW8 (Patient Set 2) was planned using
scanned electron beams and discrete energy spacing. (a) Dose plan in the sagittal-coronal, oblique
plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in transverse plane
passing through central heart region, demarcated by red line in figure (a)’s oblique plane. Upper
bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in white. Key
shows dose values.
(figure cont’d.)
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Figure B.30. Sagittal and axial images of CW8, Plan 5. CW8 (Patient Set 2) was planned using
scanned electron beams and continuous energy spacing. (a) Dose plan in the sagittal-coronal,
oblique plane demarcated by the red line in figure (b)’s transverse plane; (b) Dose plan in
transverse plane passing through central heart region, demarcated by red line in figure (a)’s oblique
plane. Upper bolus is shaded dark blue, lower bolus is shaded light blue, and PTV is outlined in
white. Key shows dose values.
(figure cont’d.)
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